|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Quercetin results in increased expression of ABCA1 mRNA]; SB 203580 inhibits the reaction [Quercetin results in increased expression of ABCA1 protein] |
CTD |
PMID:22711909 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of and affects the localization of ABCC1 protein] |
CTD |
PMID:15585369 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Anisomycin results in increased expression of ABCC3 mRNA]; SB 203580 inhibits the reaction [Clotrimazole results in increased expression of ABCC3 mRNA] |
CTD |
PMID:27507784 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]] |
CTD |
PMID:27302421 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [Amiodarone results in increased expression of ACTA2 mRNA]; SB 203580 inhibits the reaction [Amiodarone results in increased expression of ACTA2 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein] SB 203580 results in decreased expression of ACTA2 mRNA |
CTD |
PMID:11591817 PMID:21712382 PMID:28694203 PMID:29673704 PMID:31071512 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions increases secretion increases expression |
EXP ISO |
SB 203580 inhibits the reaction [Ethanol results in decreased secretion of ADIPOQ protein] SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL1 protein]; SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL8 protein] SB 203580 results in increased secretion of ADIPOQ protein SB 203580 results in increased expression of ADIPOQ mRNA |
CTD |
PMID:24412557 PMID:28176455 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
multiple interactions increases secretion |
EXP |
SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of ADM protein] SB 203580 results in increased secretion of ADM protein |
CTD |
PMID:28087833 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Vitamin A results in increased expression of AGER protein] |
CTD |
PMID:21807062 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Ago2 |
argonaute RISC catalytic component 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased localization of AGO2 protein] |
CTD |
PMID:18476811 |
|
NCBI chr 7:105,018,202...105,105,118
Ensembl chr 7:105,029,120...105,104,974
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases response to substance |
ISO EXP |
SB 203580 inhibits the reaction [AGT protein modified form results in decreased susceptibility to Acetylcholine]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG1 protein]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG2 protein] SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [AGT protein modified form results in increased activity of GATA4 protein]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 mRNA]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 protein]; SB 203580 inhibits the reaction [AGT protein results in increased expression of POSTN mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [AGT protein results in increased expression of REG3G mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of AGT protein] SB 203580 results in decreased susceptibility to AGT protein modified form |
CTD |
PMID:12130563 PMID:17485602 PMID:19145780 PMID:21108934 PMID:21289285 PMID:23300732 PMID:27798352 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions increases activity |
ISO EXP |
[alpha-naphthoflavone binds to and results in decreased activity of AHR protein] results in decreased susceptibility to [SB 203580 results in increased expression of CYP1A1]; AHR protein affects the susceptibility to [SB 203580 results in increased expression of CYP1A1] SB 203580 results in increased activity of AHR protein [SB 203580 binds to and results in increased activity of AHR protein] which results in increased susceptibility to sunitinib SB 203580 affects the localization of and affects the activity of AHR protein |
CTD |
PMID:15659807 PMID:21732638 PMID:24247421 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [nitrofen affects the localization of AIFM1 protein] SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of AIFM1 protein] |
CTD |
PMID:17439724 PMID:18506790 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akna |
AT-hook transcription factor |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [T-2 Toxin results in decreased expression of AKNA mRNA] |
CTD |
PMID:29079362 |
|
NCBI chr 5:76,777,415...76,824,380
Ensembl chr 5:76,777,415...76,816,017
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] |
CTD |
PMID:17640564 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation decreases activity |
ISO |
SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of AKT1 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased phosphorylation of AKT1 protein]; SB 203580 inhibits the reaction [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide affects the phosphorylation of AKT1 protein]; SB 203580 inhibits the reaction [Zinc results in increased phosphorylation of AKT1 protein]; SB 203580 promotes the reaction [Emodin results in decreased phosphorylation of AKT1 protein] SB 203580 results in decreased phosphorylation of AKT1 protein SB 203580 results in decreased activity of AKT1 protein |
CTD |
PMID:10998351 PMID:11788791 PMID:15980035 PMID:17341418 PMID:17640974 PMID:27032576 More...
|
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein] |
CTD |
PMID:16908450 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Calcimycin results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [Sorbitol results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [Thapsigargin results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 results in decreased phosphorylation of and results in decreased activity of ALOX5 protein SB 203580 inhibits the reaction [[Oxygen deficiency co-treated with Glucose deficiency] affects the localization of ALOX5 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide affects the localization of ALOX5 protein] SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of ALOX5 mRNA] |
CTD |
PMID:10779545 PMID:18951527 PMID:20382172 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of ALPL mRNA]] |
CTD |
PMID:25789987 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions |
ISO |
[pirinixic acid co-treated with SB 203580] inhibits the reaction [TNF protein results in decreased expression of APOA1 mRNA] |
CTD |
PMID:19883121 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein]; SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; SB 203580 inhibits the reaction [APP protein results in increased expression of NLRP3 protein]; SB 203580 inhibits the reaction [Copper results in increased expression of APP mRNA] |
CTD |
PMID:18583042 PMID:28004443 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of AQP1 protein]; SB 203580 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AQP1 protein]; SB 203580 inhibits the reaction [Peptidoglycan results in decreased expression of AQP1 protein] |
CTD |
PMID:21647617 PMID:22415096 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[ferrous chloride results in increased abundance of Iron] which results in increased expression of AQP4 protein] |
CTD |
PMID:30914277 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Areg |
amphiregulin |
decreases activity |
EXP |
SB 203580 results in decreased activity of AREG protein |
CTD |
PMID:12589827 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg1 |
arginase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG1 protein] |
CTD |
PMID:21289285 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arg2 |
arginase 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of ARG2 protein] |
CTD |
PMID:21289285 |
|
NCBI chr 6:97,936,002...97,961,379
Ensembl chr 6:97,936,002...97,961,378
|
|
G |
Arpc2 |
actin related protein 2/3 complex, subunit 2 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of ARPC2 protein] |
CTD |
PMID:24152438 |
|
NCBI chr 9:75,820,782...75,851,471
Ensembl chr 9:75,820,770...75,851,471
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO EXP |
[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Anisomycin results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of ATF1 protein] SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased phosphorylation of ATF1 protein] SB 203580 inhibits the reaction [manganese chloride results in increased phosphorylation of ATF1 protein]; SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:12660819 PMID:16424113 PMID:16787641 PMID:18579531 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of ATF2 mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein modified form]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of ATF2 protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased phosphorylation of ATF2 protein] SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of ATF2 protein] SB 203580 inhibits the reaction [dinitrophenyl-human serum albumin conjugate results in increased phosphorylation of ATF2 protein]; SB 203580 inhibits the reaction [Oxaliplatin results in increased phosphorylation of ATF2 protein] |
CTD |
PMID:10611455 PMID:18215737 PMID:19428505 PMID:21303922 PMID:23591579 PMID:24469321 PMID:26763395 PMID:27818224 PMID:28975372 More...
|
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf3 |
activating transcription factor 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of ATF3 protein]; SB 203580 inhibits the reaction [Clotrimazole results in increased expression of ATF3 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased degradation of ATF3 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased degradation of ATF3 protein] SB 203580 inhibits the reaction [Acrylamide results in increased expression of ATF3 protein] |
CTD |
PMID:19101521 PMID:25531190 PMID:27507784 PMID:33921748 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [honokiol results in increased expression of ATF4 protein] |
CTD |
PMID:33550458 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Calcitriol results in increased activity of ATG5 mRNA] |
CTD |
PMID:19748465 |
|
NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atp6v0d2 |
ATPase H+ transporting V0 subunit D2 |
multiple interactions |
ISO |
[SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of ATP6V0D2 mRNA] |
CTD |
PMID:30742845 |
|
NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:33,336,264...33,385,354
|
|
G |
Bace1 |
beta-secretase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Copper results in increased expression of BACE1 mRNA] |
CTD |
PMID:18583042 |
|
NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cadmium results in decreased activity of BACH1 protein] |
CTD |
PMID:14504288 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Sulindac affects the localization of BAK1 protein] |
CTD |
PMID:17136320 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO EXP |
saikosaponin D promotes the reaction [SB 203580 results in increased expression of BAX protein]; SB 203580 affects the reaction [Emodin affects the expression of BAX protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased expression of BAX protein]; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of BAX protein]; SB 203580 inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased localization of BAX protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole analog results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Fenbendazole results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of BAX protein]; SB 203580 inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) affects the localization of BAX protein]; SB 203580 inhibits the reaction [Stilbenes analog affects the localization of BAX protein]; SB 203580 inhibits the reaction [Sulindac affects the localization of BAX protein]; SB 203580 promotes the reaction [Resveratrol results in increased activity of BAX protein] SB 203580 inhibits the reaction [Cisplatin results in increased expression of BAX protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased expression of BAX protein]]; SB 203580 inhibits the reaction [Oxaliplatin results in increased expression of BAX protein]; SB 203580 promotes the reaction [Cisplatin results in increased expression of BAX protein] SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which affects the localization of BAX protein]; SB 203580 inhibits the reaction [chloroacetic acid results in increased expression of BAX mRNA] |
CTD |
PMID:17136320 PMID:17237268 PMID:18449500 PMID:19428505 PMID:19578154 PMID:21420390 PMID:22644961 PMID:22878015 PMID:23103613 PMID:23994742 PMID:24036456 PMID:27032576 PMID:30653946 PMID:32890875 PMID:33285147 PMID:35499276 PMID:35569513 PMID:37769856 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
ISO EXP |
saikosaponin D promotes the reaction [SB 203580 results in decreased expression of BCL2 protein]; SB 203580 affects the reaction [Emodin affects the expression of BCL2 protein]; SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide affects the localization of BCL2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 mRNA]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in decreased expression of BCL2 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein] SB 203580 inhibits the reaction [chloroacetic acid results in decreased expression of BCL2 mRNA]; SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of BCL2 mRNA] SB 203580 inhibits the reaction [Cisplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein]; SB 203580 inhibits the reaction [oxaliplatin results in increased phosphorylation of and results in decreased activity of BCL2 protein] |
CTD |
PMID:16782274 PMID:16818652 PMID:19428505 PMID:21420390 PMID:23103613 PMID:23994742 PMID:24036456 PMID:25446857 PMID:27032576 PMID:30653946 PMID:30871965 PMID:32890875 PMID:34303041 PMID:35499276 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions |
EXP |
SB 203580 promotes the reaction [Cisplatin results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19578154 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479 Ensembl chr 1:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of BCL2L11 protein] |
CTD |
PMID:16818494 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl3 |
BCL3, transcription coactivator |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of BCL3 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
|
|
G |
Becn1 |
beclin 1 |
multiple interactions decreases expression |
ISO EXP |
SB 203580 inhibits the reaction [Calcitriol results in increased activity of BECN1 mRNA] SB203580 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells SB 203580 inhibits the reaction [decamethrin results in increased expression of BECN1 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in decreased expression of BECN1 protein]] |
CTD RGD |
PMID:19748465 PMID:26588882 PMID:37769856 PMID:27769861 |
RGD:329853763 |
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of BGLAP protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of BGLAP protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of BGLAP protein] |
CTD |
PMID:26136938 PMID:31472278 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
SB 203580 promotes the reaction [Emodin results in increased degradation of BID protein] |
CTD |
PMID:27032576 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions increases expression |
ISO |
SB 203580 affects the reaction [[gambogic acid co-treated with Doxorubicin] affects the expression of BIRC5 protein]; SB 203580 inhibits the reaction [arsenic trioxide results in decreased expression of BIRC5 protein]; SB 203580 inhibits the reaction [baicalein results in decreased expression of BIRC5 protein]; SB 203580 inhibits the reaction [tanshinone results in decreased expression of BIRC5 mRNA] SB 203580 results in increased expression of BIRC5 mRNA |
CTD |
PMID:16328441 PMID:18025287 PMID:21165580 PMID:21594580 PMID:25824409 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
decreases expression multiple interactions |
ISO EXP |
SB 203580 results in decreased expression of BMP2 mRNA SB 203580 inhibits the reaction [Quercetin results in increased expression of BMP2 mRNA] SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of ALPL mRNA]]; SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP2 mRNA]]; SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP6 mRNA]]; SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP7 mRNA]]; SB 203580 inhibits the reaction [5-Methoxypsoralen results in increased expression of BMP2 mRNA]; SB 203580 inhibits the reaction [imperatorin results in increased expression of BMP2 mRNA] |
CTD |
PMID:17980360 PMID:20660070 PMID:25789987 PMID:26136938 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp6 |
bone morphogenetic protein 6 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP6 mRNA]] SB 203580 promotes the reaction [tricetin results in decreased expression of BMP6 protein] |
CTD |
PMID:25789987 PMID:38654487 |
|
NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365
|
|
G |
Bmp7 |
bone morphogenetic protein 7 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [(4-(7-chloroquinolin-4-yl)piperazino)(1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)methanone promotes the reaction [BMP2 protein results in increased expression of BMP7 mRNA]] |
CTD |
PMID:25789987 |
|
NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788
|
|
G |
Bsg |
basigin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of BSG protein] |
CTD |
PMID:18647594 |
|
NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387
|
|
G |
Cacna1g |
calcium voltage-gated channel subunit alpha1 G |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [telmisartan results in decreased expression of CACNA1G mRNA] |
CTD |
PMID:19292980 |
|
NCBI chr10:79,354,998...79,422,960
Ensembl chr10:79,355,008...79,422,752
|
|
G |
Cacna1h |
calcium voltage-gated channel subunit alpha1 H |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [telmisartan results in decreased expression of CACNA1H mRNA] |
CTD |
PMID:19292980 |
|
NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
multiple interactions |
ISO |
SB 203580 promotes the reaction [Calcitriol promotes the reaction [resveratrol results in increased expression of CAMP mRNA]]; SB 203580 promotes the reaction [resveratrol promotes the reaction [Calcitriol results in increased expression of CAMP mRNA]] |
CTD |
PMID:24039193 |
|
NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of CASP1 protein] SB 203580 inhibits the reaction [Acrolein results in increased cleavage of CASP1 protein] |
CTD |
PMID:28004443 PMID:31639409 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
ISO EXP |
saikosaponin D promotes the reaction [SB 203580 results in increased cleavage of and results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [(1R,3S,3aR,8bS)-3a-(4-Bromophenyl)-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-1,8b-diol results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one) results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which results in increased expression of and results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Acetaldehyde results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Biological Products results in increased expression of CASP3 mRNA]; SB 203580 inhibits the reaction [cantharidic acid results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 protein modified form]; SB 203580 inhibits the reaction [DDT results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Emodin results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [ferruginol results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; SB 203580 inhibits the reaction [licochalcone A results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [malvidin results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Paraquat results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Pyrogallol results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Thimerosal results in increased activity of CASP3 protein]; SB 203580 promotes the reaction [Cadmium results in increased activity of and results in increased cleavage of CASP3 protein]; SB 203580 promotes the reaction [Resveratrol results in increased activity of CASP3 protein]; SB 203580 results in increased cleavage of and results in increased activity of CASP3 protein SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased cleavage of and results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Cocaine results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [decamethrin results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased expression of CASP3 protein]]; SB 203580 inhibits the reaction [satratoxin H results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [tributyltin results in increased expression of CASP3 protein]; SB 203580 promotes the reaction [Cadmium results in increased activity of and results in increased cleavage of CASP3 protein]; SB 203580 promotes the reaction [Cisplatin results in increased activity of CASP3 protein] SB 203580 inhibits the reaction [[GMFB protein co-treated with Hydrogen Peroxide] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [chloroacetic acid results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Methylmercury Compounds results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Morphine results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Uranyl Nitrate results in increased activity of CASP3 protein] SB 203580 results in increased expression of CASP3 protein modified form |
CTD |
PMID:12791701 PMID:14722101 PMID:15050407 PMID:15365088 PMID:15603917 PMID:15964118 PMID:15976193 PMID:17237268 PMID:17341418 PMID:17698513 PMID:19194971 PMID:19578154 PMID:20191265 PMID:20600172 PMID:21295052 PMID:21549813 PMID:21732360 PMID:21998720 PMID:22644961 PMID:22654482 PMID:22863859 PMID:22878015 PMID:23103613 PMID:23300732 PMID:23416140 PMID:23743147 PMID:23994742 PMID:24036456 PMID:24607276 PMID:24824807 PMID:25446857 PMID:26529667 PMID:26588882 PMID:27032576 PMID:28383207 PMID:28391263 PMID:29159945 PMID:29297590 PMID:30086653 PMID:30871965 PMID:30928397 PMID:30983163 PMID:31381934 PMID:31916385 PMID:32890875 PMID:33285147 PMID:33592258 PMID:34303041 PMID:37769856 PMID:37782689 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp6 |
caspase 6 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Indomethacin results in increased activity of CASP6 protein] |
CTD |
PMID:17341418 |
|
NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [DDT results in increased activity of CASP7 protein] SB 203580 inhibits the reaction [chloroacetic acid results in increased activity of CASP7 protein] |
CTD |
PMID:15603917 PMID:23103613 |
|
NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[Resveratrol co-treated with SB 203580] results in increased activity of CASP8 protein; SB 203580 inhibits the reaction [(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one) results in increased cleavage of CASP8 protein]; SB 203580 inhibits the reaction [cantharidic acid results in increased cleavage of CASP8 protein]; SB 203580 inhibits the reaction [licochalcone A results in increased cleavage of CASP8 protein]; SB 203580 promotes the reaction [Emodin results in increased activity of CASP8 protein] |
CTD |
PMID:22644961 PMID:27032576 PMID:29159945 PMID:30983163 PMID:31916385 PMID:37782689 More...
|
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO EXP |
[Resveratrol co-treated with SB 203580] results in increased activity of CASP9 protein; SB 203580 inhibits the reaction [(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one) results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [[Arsenic Trioxide co-treated with phytosphingosine] results in increased activity of CASP9 protein]; SB 203580 inhibits the reaction [cantharidic acid results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased activity of CASP9 protein]; SB 203580 inhibits the reaction [licochalcone A results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in increased activity of CASP9 protein] SB 203580 inhibits the reaction [[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate] results in increased cleavage of CASP9 protein]; SB 203580 inhibits the reaction [Cocaine results in increased activity of CASP9 protein] |
CTD |
PMID:15365088 PMID:17237268 PMID:17341418 PMID:21420390 PMID:22644961 PMID:26396915 PMID:29159945 PMID:30983163 PMID:31916385 PMID:37782689 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
SB 203580 promotes the reaction [Pyrogallol results in decreased expression of CAT protein] |
CTD |
PMID:20191265 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cav1 |
caveolin 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Hydrogen Peroxide promotes the reaction [SP1 protein results in increased expression of CAV1 protein]]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of CAV1 protein] [SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of CAV1 protein]; SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of CAV1 mRNA]; SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of CAV1 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CAV1 protein] |
CTD |
PMID:14984747 PMID:17108117 PMID:21457723 PMID:25512378 |
|
NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL11 protein] |
CTD |
PMID:23707484 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Allopurinol results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [chlorobenzene results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Diclofenac analog results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Folic Acid deficiency results in increased expression of and results in increased secretion of CCL2 protein]; SB 203580 inhibits the reaction [Folic Acid deficiency results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [melamine results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Particulate Matter analog results in decreased secretion of CCL2 protein]; SB 203580 inhibits the reaction [TNF results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in decreased secretion of CCL2 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dermatophagoides pteronyssinus antigen p 1 results in increased secretion of CCL2 protein]]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter analog results in decreased secretion of CCL2 protein]]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Vehicle Emissions analog results in decreased secretion of CCL2 protein]] SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CCL2 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of CCL2 protein] SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA] |
CTD |
PMID:10919993 PMID:12016129 PMID:16143069 PMID:17655880 PMID:18645721 PMID:19020780 PMID:19132243 PMID:19152916 PMID:20712904 PMID:22915474 PMID:24104198 PMID:24376630 PMID:26641773 PMID:26862037 PMID:28087833 PMID:28329830 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl26 |
C-C motif chemokine ligand 26 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [CCL26 protein binds to and results in increased activity of CCR3 protein] |
CTD |
PMID:37788752 |
|
NCBI chr12:21,109,384...21,114,336
Ensembl chr12:21,109,421...21,114,335
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Methotrexate results in decreased expression of CCL3 protein] |
CTD |
PMID:19100307 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
multiple interactions |
ISO |
SB 203580 affects the reaction [Methotrexate results in decreased expression of CCL4 protein] |
CTD |
PMID:19100307 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; SB 203580 inhibits the reaction [Dermatophagoides pteronyssinus antigen p 1 results in increased secretion of CCL5 protein]; SB 203580 inhibits the reaction [Particulate Matter analog results in increased secretion of CCL5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in increased secretion of CCL5 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter analog results in decreased secretion of CCL5 protein]]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Vehicle Emissions analog results in decreased secretion of CCL5 protein]]; SB 203580 promotes the reaction [Methotrexate results in increased expression of CCL5 protein] |
CTD |
PMID:10919993 PMID:11167962 PMID:16908450 PMID:19100307 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCL7 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression multiple interactions |
ISO |
SB 203580 results in increased expression of CCN1 protein [sclareol co-treated with SB 203580] results in increased expression of CCN1 protein |
CTD |
PMID:33423118 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
multiple interactions decreases expression |
ISO |
SB 203580 analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]; SB 203580 inhibits the reaction [Glucose results in increased expression of CCN2 protein] SB 203580 results in decreased expression of CCN2 protein |
CTD |
PMID:19369054 PMID:20864298 PMID:26054450 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [ochratoxin A inhibits the reaction [CDK1 protein binds to CCNB1 protein]]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CCNB1 protein] |
CTD |
PMID:22230261 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions decreases expression |
ISO EXP |
SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND1 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CCND1 protein] SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of CCND1 protein] SB 203580 results in decreased expression of CCND1 protein |
CTD |
PMID:21712382 PMID:23112108 PMID:30801954 PMID:32890875 PMID:34571074 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND3 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CCND3 protein] |
CTD |
PMID:23112108 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of CCR2 protein] |
CTD |
PMID:26163174 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Ccr3 |
C-C motif chemokine receptor 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [CCL26 protein binds to and results in increased activity of CCR3 protein] |
CTD |
PMID:37788752 |
|
NCBI chr 8:123,586,100...123,634,178
Ensembl chr 8:123,616,236...123,634,990
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CCR7 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD14 protein] |
CTD |
PMID:18180316 PMID:20226526 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased cleavage of CD38 protein] |
CTD |
PMID:15494208 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd63 |
Cd63 molecule |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Mustard Gas promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of CD63 protein]] |
CTD |
PMID:22036725 |
|
NCBI chr 7:1,325,108...1,340,447
Ensembl chr 7:1,325,103...1,399,178
|
|
G |
Cd83 |
CD83 molecule |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD83 protein]; SB 203580 inhibits the reaction [Zymosan results in increased expression of CD83 protein] |
CTD |
PMID:17698565 |
|
NCBI chr17:20,887,309...20,907,009
Ensembl chr17:20,887,309...20,907,083
|
|
G |
Cd86 |
CD86 molecule |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [1,10-phenanthroline results in increased expression of CD86 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased expression of CD86 protein]; SB 203580 inhibits the reaction [Zymosan results in increased expression of CD86 protein] |
CTD |
PMID:17698565 PMID:19641517 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDC25C protein modified form]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDC25C protein] |
CTD |
PMID:22230261 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdc6 |
cell division cycle 6 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [arsenic trioxide results in increased expression of CDC6 protein] |
CTD |
PMID:20862710 |
|
NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein] |
CTD |
PMID:28694203 PMID:33396024 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh5 |
cadherin 5 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Varenicline results in decreased expression of CDH5] |
CTD |
PMID:28842382 |
|
NCBI chr19:815,415...854,478
Ensembl chr19:815,411...854,368
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [baicalein results in decreased phosphorylation of CDK1 protein]; SB 203580 inhibits the reaction [ochratoxin A inhibits the reaction [CDK1 protein binds to CCNB1 protein]]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDK1 protein modified form]; SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of CDK1 protein] |
CTD |
PMID:18025287 PMID:22230261 |
|
NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [sodium arsenite results in decreased activity of CDK2 protein] SB 203580 inhibits the reaction [esculetin results in decreased expression of CDK2 protein] |
CTD |
PMID:11807808 PMID:21600278 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [esculetin results in decreased expression of CDK4 protein] |
CTD |
PMID:21600278 |
|
NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [resveratrol results in decreased expression of CDK5R1 mRNA] |
CTD |
PMID:21736731 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdk6 |
cyclin-dependent kinase 6 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Furazolidone results in increased expression of CDK6 mRNA]; SB 203580 inhibits the reaction [Furazolidone results in increased expression of CDK6 protein] |
CTD |
PMID:23112108 |
|
NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Cadmium results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] SB 203580 inhibits the reaction [esculetin results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [pyrrolidine dithiocarbamic acid results in increased expression of CDKN1A protein] SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of CDKN1A mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A protein]; SB 203580 inhibits the reaction [Methylcholanthrene results in increased expression of CDKN1A mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] |
CTD |
PMID:11807808 PMID:14603533 PMID:14647439 PMID:15734884 PMID:15882963 PMID:17108117 PMID:19082730 PMID:21600278 PMID:28329830 More...
|
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased expression of CDKN1B protein] |
CTD |
PMID:19082730 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of CDKN2A protein] |
CTD |
PMID:31734849 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdon |
cell adhesion associated, oncogene regulated |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [bakuchiol results in increased expression of CDON protein] |
CTD |
PMID:26902638 |
|
NCBI chr 8:33,775,123...33,861,635
Ensembl chr 8:33,806,183...33,859,033
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPA protein] |
CTD |
PMID:24376792 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPB protein]; SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of CEBPB protein] |
CTD |
PMID:16355272 PMID:24376792 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Glucose results in increased localization of and results in increased activity of CEBPD protein] |
CTD |
PMID:24376792 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CES1 mRNA] |
CTD |
PMID:21237253 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CES2 mRNA] |
CTD |
PMID:21237253 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Chrm3 |
cholinergic receptor, muscarinic 3 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Particulate Matter results in increased expression of CHRM3 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of CHRM3 protein] |
CTD |
PMID:26916448 |
|
NCBI chr17:60,005,137...60,467,250
Ensembl chr17:60,005,202...60,467,278
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of CHUK protein] |
CTD |
PMID:19616567 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cldn1 |
claudin 1 |
multiple interactions increases expression |
ISO |
[SB 203580 co-treated with Dextran Sulfate] results in decreased expression of CLDN1 protein SB 203580 results in increased expression of CLDN1 protein |
CTD |
PMID:27920472 PMID:34506768 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn11 |
claudin 11 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CLDN11 protein] |
CTD |
PMID:23761298 |
|
NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:112,207,745...112,221,050
|
|
G |
Cldn2 |
claudin 2 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B protein] |
CTD |
PMID:15350541 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Cnn1 |
calponin 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of CNN1 protein] |
CTD |
PMID:21712382 |
|
NCBI chr 8:20,632,434...20,641,097
Ensembl chr 8:20,632,338...20,641,098
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR1 protein] |
CTD |
PMID:27920472 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of CNR2 protein] |
CTD |
PMID:27920472 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of COL18A1 mRNA] SB 203580 results in decreased expression of COL18A1 mRNA |
CTD |
PMID:13679210 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions decreases expression |
ISO EXP |
SB 203580 inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA] SB 203580 inhibits the reaction [Acetaldehyde results in increased expression of COL1A1 mRNA] SB 203580 results in decreased expression of COL1A1 mRNA |
CTD |
PMID:12065697 PMID:18253093 PMID:27235791 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of COL1A2 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of COL1A2 protein] |
CTD |
PMID:31472278 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cp |
ceruloplasmin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [CP protein results in increased abundance of Nitrites] |
CTD |
PMID:17727827 |
|
NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Formaldehyde results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of CREB1 protein] [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in increased phosphorylation of CREB1 protein] SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [AGT protein results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [manganese chloride results in increased phosphorylation of CREB1 protein]; SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of CREB1 protein] SB 203580 results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:12660819 PMID:14741741 PMID:16424113 PMID:16787641 PMID:19145780 PMID:22138297 PMID:25605016 PMID:28049186 PMID:28087833 PMID:28601556 PMID:30951808 PMID:33359577 PMID:34571074 More...
|
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crebbp |
CREB binding protein |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [o,p'-DDT results in increased activity of CREBBP protein] |
CTD |
PMID:22609851 |
|
NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
|
|
G |
Crh |
corticotropin releasing hormone |
multiple interactions |
EXP ISO |
SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of CRH mRNA] SB 203580 inhibits the reaction [2,2',4,4'-tetrabromodiphenyl ether results in increased expression of CRH mRNA] |
CTD |
PMID:21959975 PMID:28189027 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Crp |
C-reactive protein |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[IL1B protein co-treated with IL6 protein] results in increased expression of and results in increased secretion of CRP protein] |
CTD |
PMID:17388968 |
|
NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Crtc2 |
CREB regulated transcription coactivator 2 |
multiple interactions |
ISO |
[N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of CRTC2 protein] |
CTD |
PMID:33359577 |
|
NCBI chr 2:175,709,603...175,719,768
Ensembl chr 2:175,709,644...175,719,763
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
[SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of ATP6V0D2 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] |
CTD |
PMID:30742845 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased secretion of CSF2 protein] |
CTD |
PMID:10645887 PMID:16908450 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [DEFA1 protein results in decreased phosphorylation of and results in increased activity of CTNNB1 protein]; SB 203580 inhibits the reaction [DEFA2 protein results in decreased phosphorylation of and results in increased activity of CTNNB1 protein] |
CTD |
PMID:19814765 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsk |
cathepsin K |
multiple interactions |
ISO |
[SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] |
CTD |
PMID:30742845 |
|
NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550
|
|
G |
Cx3cl1 |
C-X3-C motif chemokine ligand 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Glucose results in increased expression of CX3CL1 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of CX3CL1 protein] |
CTD |
PMID:19132243 |
|
NCBI chr19:10,227,337...10,237,826
Ensembl chr19:10,227,340...10,236,833
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions decreases secretion |
EXP ISO |
SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of CXCL1 protein]; SB 203580 inhibits the reaction [resveratrol results in decreased expression of CXCL1 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of CXCL1 protein] SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of CXCL1 protein] SB 203580 results in decreased secretion of CXCL1 protein |
CTD |
PMID:21192278 PMID:23285267 PMID:28087833 PMID:28176455 PMID:35006638 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein]; SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CXCL2 protein]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli results in increased expression of CXCL2 protein]]; SB 203580 inhibits the reaction [Paraquat results in increased expression of CXCL2 protein] SB 203580 inhibits the reaction [nickel monoxide results in increased expression of CXCL2 protein] SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of CXCL2 protein]; SB 203580 inhibits the reaction [resveratrol results in decreased expression of CXCL2 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of CXCL2 protein] |
CTD |
PMID:16919916 PMID:21192278 PMID:21507677 PMID:23285267 PMID:24376630 PMID:35006638 More...
|
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [ADIPOQ protein results in increased expression of CXCL1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of CXCL1 protein] |
CTD |
PMID:28176455 PMID:35006638 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cxcr2 |
C-X-C motif chemokine receptor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Lipopolysaccharides results in decreased expression of CXCR2 protein] |
CTD |
PMID:10950785 |
|
NCBI chr 9:75,729,493...75,735,868
Ensembl chr 9:75,729,115...75,739,425
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Ethanol results in increased expression of CYBA mRNA] |
CTD |
PMID:23978445 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Ethanol results in increased expression of CYBB mRNA] |
CTD |
PMID:23978445 |
|
NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP ISO |
SB 203580 promotes the reaction [Cisplatin affects the localization of CYCS protein] SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased expression of CYCS protein] |
CTD |
PMID:19578154 PMID:30653946 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 mRNA]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP11A1 protein] |
CTD |
PMID:29567110 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 mRNA]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of CYP17A1 protein] |
CTD |
PMID:29567110 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity multiple interactions increases expression |
ISO EXP |
SB 203580 results in increased activity of CYP1A1 protein SB203580 increases expression of mRNA and potentiates the reaction [sunitinib increases expression of mRNA] in rat cardiomyocytes SB 203580 inhibits the reaction [Nicotine results in increased expression of CYP1A1 mRNA] SB 203580 results in increased expression of CYP1A1 mRNA SB 203580 promotes the reaction [sunitinib results in increased expression of CYP1A1 mRNA] SB 203580 results in increased expression of CYP1A1 mRNA; SB 203580 results in increased expression of CYP1A1 protein [alpha-naphthoflavone binds to and results in decreased activity of AHR protein] results in decreased susceptibility to [SB 203580 results in increased expression of CYP1A1]; AHR protein affects the susceptibility to [SB 203580 results in increased expression of CYP1A1]; Dactinomycin inhibits the reaction [SB 203580 results in increased expression of CYP1A1 mRNA]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1]; SB 203580 results in increased expression of and results in increased activity of CYP1A1 protein |
CTD RGD |
PMID:18078826 PMID:21732638 PMID:24247421 PMID:34171359 PMID:24247421 |
RGD:401793741 |
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp27b1 |
cytochrome P450, family 27, subfamily b, polypeptide 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [IFNG protein results in increased expression of CYP27B1 mRNA] |
CTD |
PMID:16355272 |
|
NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:62,871,297...62,876,241
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions |
ISO |
SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] |
CTD |
PMID:22486562 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Daxx |
death-domain associated protein |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of DAXX protein] |
CTD |
PMID:12508112 |
|
NCBI chr20:4,970,090...4,976,145
Ensembl chr20:4,970,092...4,975,843
|
|
G |
Dct |
dopachrome tautomerase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cannabidiol results in increased expression of DCT mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [baicalein-7-O-diglucoside results in increased expression of DDIT3 protein]; SB 203580 inhibits the reaction [honokiol results in increased expression of DDIT3 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased expression of DDIT3 protein] SB 203580 inhibits the reaction [alpha-naphthoflavone results in increased expression of DDIT3 protein] |
CTD |
PMID:17341418 PMID:26253462 PMID:30508555 PMID:33550458 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DDIT4 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Dio2 |
iodothyronine deiodinase 2 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of DIO2 mRNA] |
CTD |
PMID:18420745 |
|
NCBI chr 6:109,665,523...109,679,809
Ensembl chr 6:109,665,523...109,679,809
|
|
G |
Dio3 |
iodothyronine deiodinase 3 |
decreases expression multiple interactions |
ISO EXP |
SB 203580 results in decreased expression of DIO3 SB 203580 inhibits the reaction [Fluoxetine results in increased expression of DIO3 mRNA]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased activity of DIO3 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of DIO3 mRNA] |
CTD |
PMID:15456934 PMID:18420745 PMID:26825960 |
|
NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
|
|
G |
Dnajb9 |
DnaJ heat shock protein family (Hsp40) member B9 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DNAJB9 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [arsenite results in increased expression of DUSP1 mRNA] SB 203580 inhibits the reaction [Cadmium results in increased expression of DUSP1 mRNA]; SB 203580 inhibits the reaction [Cadmium results in increased expression of DUSP1 protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of DUSP1 mRNA]; SB 203580 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of DUSP1 protein] |
CTD |
PMID:11577072 PMID:11689710 PMID:18573614 PMID:20885979 |
|
NCBI chr10:16,680,478...16,683,275
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of DUSP5 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Asbestos, Crocidolite results in increased expression of DUSP6 mRNA] |
CTD |
PMID:18314537 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Ece1 |
endothelin converting enzyme 1 |
affects expression |
EXP |
SB 203580 affects the expression of ECE1 mRNA |
CTD |
PMID:21084678 |
|
NCBI chr 5:150,077,679...150,179,375
Ensembl chr 5:150,077,644...150,179,371
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [cobaltous chloride results in increased secretion of EDN1 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of CXCL8 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of EDN1 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [Glucose results in increased expression of EDN1 mRNA] SB 203580 inhibits the reaction [EDN1 protein results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:14741741 PMID:18457675 PMID:24376792 PMID:27297870 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRA protein] |
CTD |
PMID:36183783 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB mRNA]; SB 203580 inhibits the reaction [Cyclosporine results in increased expression of EDNRB protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of EDNRB protein]; SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB mRNA]; SB 203580 inhibits the reaction [Smoke results in increased expression of EDNRB protein] |
CTD |
PMID:18718921 PMID:20561571 PMID:25772258 PMID:26496744 PMID:36183783 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein] SB 203580 results in decreased activity of [arsenite co-treated with EGF protein] |
CTD |
PMID:9733710 PMID:22766066 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Fluorouracil results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Fluorouracil results in increased expression of EGR1 protein]; SB 203580 promotes the reaction [3,4-dihydroxyphenylethanol results in increased expression of EGR1 mRNA]; SB 203580 promotes the reaction [pyrrolidine dithiocarbamic acid results in increased expression of EGR1 mRNA]; SB 203580 promotes the reaction [Resveratrol results in increased expression of EGR1 mRNA] SB 203580 inhibits the reaction [Quercetin results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Quercetin results in increased expression of EGR1 protein] SB 203580 inhibits the reaction [Anisomycin results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of EGR1 mRNA]; SB 203580 inhibits the reaction [Particulate Matter promotes the reaction [Tobacco Smoke Pollution results in increased expression of EGR1 mRNA]]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution promotes the reaction [Particulate Matter results in increased expression of EGR1 mRNA]]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution results in increased expression of EGR1 mRNA]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of EGR1 mRNA] |
CTD |
PMID:9671412 PMID:12482581 PMID:18757417 PMID:22046279 PMID:22174042 PMID:22178768 More...
|
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation |
ISO |
SB 203580 results in increased phosphorylation of EIF2S1 protein |
CTD |
PMID:21090173 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]; MAPK14 protein mutant form inhibits the reaction [SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of EIF4E protein]]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of EIF4E protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4E protein]] [SB 203580 co-treated with U 0126] inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of EIF4E protein] |
CTD |
PMID:9545260 PMID:12781867 PMID:16431125 |
|
NCBI chr 2:227,066,519...227,099,261
Ensembl chr 2:227,066,673...227,098,683
|
|
G |
Eif4g1 |
eukaryotic translation initiation factor 4 gamma 1 |
multiple interactions |
ISO |
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of EIF4G1 protein] |
CTD |
PMID:12781867 |
|
NCBI chr11:80,221,919...80,241,958
Ensembl chr11:80,221,919...80,241,941
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions affects activity |
ISO EXP |
[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [sodium arsenite results in increased phosphorylation of ELK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of ELK1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of ELK1 protein] SB 203580 affects the activity of ELK1 protein |
CTD |
PMID:10903806 PMID:12660819 PMID:21084678 PMID:21642427 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Enc1 |
ectodermal-neural cortex 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of ENC1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Doxorubicin results in decreased expression of EP300 protein]; SB 203580 inhibits the reaction [MAP2K6 protein results in decreased expression of EP300 protein] |
CTD |
PMID:15767673 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CXCL8 mRNA]]; SB 203580 inhibits the reaction [ERBB2 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased secretion of CXCL8 protein]] |
CTD |
PMID:33396024 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
increases expression multiple interactions |
ISO |
SB 203580 results in increased expression of ERCC1 mRNA SB 203580 inhibits the reaction [tanshinone results in decreased expression of ERCC1 mRNA] |
CTD |
PMID:21165580 |
|
NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963
|
|
G |
Errfi1 |
ERBB receptor feedback inhibitor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of ERRFI1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions decreases expression |
ISO |
[SB 203580 co-treated with naringenin] results in increased degradation of ESR1 protein; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [Estradiol results in increased degradation of ESR1 protein] SB 203580 results in decreased expression of ESR1 protein SB 203580 inhibits the reaction [Estradiol results in increased expression of ESR1 protein] |
CTD |
PMID:19194971 PMID:19340542 PMID:24586459 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:21732360 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Ets1 |
ETS proto-oncogene 1, transcription factor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ETS1 mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of ETS1 mRNA]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of ETS1 mRNA] |
CTD |
PMID:21635667 |
|
NCBI chr 8:31,045,909...31,168,010
Ensembl chr 8:31,045,945...31,168,010
|
|
G |
Ezr |
ezrin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of EZR protein] |
CTD |
PMID:24677693 |
|
NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505
|
|
G |
F11r |
F11 receptor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Poly I-C results in decreased expression of F11R protein] |
CTD |
PMID:20932985 |
|
NCBI chr13:83,873,797...83,897,388
Ensembl chr13:83,873,797...83,897,402
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [Asbestos, Crocidolite results in increased expression of F3 mRNA]; SB 203580 inhibits the reaction [Histamine results in increased expression of F3]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of F3 protein]; SB 203580 inhibits the reaction [indoleacetic acid results in increased expression of F3 mRNA]; SB 203580 inhibits the reaction [indoleacetic acid results in increased expression of F3 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of F3 mRNA] SB 203580 results in decreased expression of F3 mRNA |
CTD |
PMID:15371228 PMID:16009787 PMID:20118172 PMID:27556861 PMID:30324315 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]] |
CTD |
PMID:31067004 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fancd2 |
FA complementation group D2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Ouabain inhibits the reaction [Mitomycin results in increased expression of and affects the ubiquitination of FANCD2 protein]] |
CTD |
PMID:24124520 |
|
NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FADD protein]]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]] |
CTD |
PMID:31067004 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
SB 203580 affects the reaction [Temozolomide results in increased expression of FASLG mRNA]; SB 203580 inhibits the reaction [S-allylcysteine promotes the reaction [FAS protein binds to FASLG protein]]; SB 203580 promotes the reaction [Emodin results in increased expression of FASLG protein]; SB 203580 promotes the reaction [Resveratrol results in increased cleavage of FASLG protein] SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of FASL mRNA] |
CTD |
PMID:16782274 PMID:22644961 PMID:26418950 PMID:27032576 PMID:31067004 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
multiple interactions increases secretion decreases activity |
ISO EXP |
SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of RB1 protein]; SB 203580 inhibits the reaction [Sodium Chloride results in increased expression of FGF2 mRNA] SB 203580 results in increased secretion of FGF2 protein SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 mRNA]; SB 203580 inhibits the reaction [AGT protein modified form results in increased expression of FGF2 protein]; SB 203580 promotes the reaction [diphenylarsinic acid results in increased secretion of FGF2 protein] SB 203580 inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein] SB 203580 results in decreased activity of FGF2 protein |
CTD |
PMID:15249425 PMID:15631803 PMID:21108934 PMID:25290095 PMID:26800359 PMID:28087833 More...
|
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Fgf23 |
fibroblast growth factor 23 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [FGF23 protein results in increased chemical synthesis of and affects the secretion of Dinoprostone] |
CTD |
PMID:16144964 |
|
NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:159,914,272...159,923,821
|
|
G |
Fgf7 |
fibroblast growth factor 7 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of FGF7 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [[sphingosine 1-phosphate co-treated with Glucose] results in increased expression of FN1 protein]; SB 203580 inhibits the reaction [Pyruvaldehyde results in increased expression of FN1 mRNA] |
CTD |
PMID:17635749 PMID:22406263 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions decreases expression increases expression |
ISO EXP |
SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased expression of FOS protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of FOS mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of FOS protein]; SB 203580 inhibits the reaction [Nicotine results in increased phosphorylation of FOS protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of FOS mRNA] SB 203580 promotes the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of FOS protein] SB 203580 results in decreased expression of FOS mRNA SB 203580 results in increased expression of FOS protein SB 203580 inhibits the reaction [icariin results in increased expression of FOS protein] |
CTD |
PMID:11053056 PMID:12547826 PMID:15322261 PMID:18423597 PMID:18982426 PMID:21084678 PMID:21219922 PMID:26814129 PMID:27393034 PMID:28087833 PMID:34171359 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of FOSL1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Foxo3 |
forkhead box O3 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Cadmium Chloride results in decreased activity of FOXO3 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein] SB 203580 inhibits the reaction [Manganese results in increased phosphorylation of FOXO3 protein] |
CTD |
PMID:23673518 PMID:24787138 |
|
NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561
|
|
G |
Fshb |
follicle stimulating hormone subunit beta |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [FSHB protein results in increased abundance of Estradiol] |
CTD |
PMID:22067323 |
|
NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370
|
|
G |
Gabpa |
GA binding protein transcription factor subunit alpha |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Gallic Acid results in increased expression of GABPA protein] |
CTD |
PMID:16308312 |
|
NCBI chr11:23,888,586...23,917,612
Ensembl chr11:23,888,815...23,917,605
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions |
ISO |
troglitazone promotes the reaction [SB 203580 results in increased expression of GADD45A mRNA] |
CTD |
PMID:15064713 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Galnt3 |
polypeptide N-acetylgalactosaminyltransferase 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cadmium results in increased expression of GALNT3 mRNA] |
CTD |
PMID:24614234 |
|
NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:50,742,512...50,766,268
|
|
G |
Gata2 |
GATA binding protein 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of GATA2 protein] |
CTD |
PMID:23940812 |
|
NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761
|
|
G |
Gata4 |
GATA binding protein 4 |
affects activity multiple interactions |
EXP |
SB 203580 affects the activity of GATA4 protein SB 203580 inhibits the reaction [AGT protein modified form results in increased activity of GATA4 protein] |
CTD |
PMID:21084678 PMID:21108934 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gcg |
glucagon |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Chitosan results in increased expression of GCG mRNA]; SB 203580 inhibits the reaction [Chitosan results in increased secretion of GCG protein] |
CTD |
PMID:23611362 |
|
NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Plant Extracts results in increased expression of GCLC protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of GCLC protein] SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone results in increased expression of GCLC mRNA] |
CTD |
PMID:25201354 PMID:30626086 PMID:31029725 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Quercetin results in increased expression of GCLM mRNA] |
CTD |
PMID:22197970 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gdf15 |
growth differentiation factor 15 |
multiple interactions |
ISO |
[SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [jasplakinolide results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [latrunculin B results in increased expression of GDF15 protein]; [SB 203580 co-treated with 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of GDF15 protein]; SB 203580 inhibits the reaction [rottlerin results in increased expression of GDF15 protein]; SB 203580 inhibits the reaction [silybin results in increased expression of GDF15 protein] |
CTD |
PMID:22410117 PMID:23996089 PMID:24440808 |
|
NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of GFAP protein] |
CTD |
PMID:34571074 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Ggt1 |
gamma-glutamyltransferase 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of GGT1 mRNA] |
CTD |
PMID:16195535 |
|
NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of GH1 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of GH1 protein]; SB 203580 inhibits the reaction [T-2 Toxin results in decreased expression of GH1 mRNA] |
CTD |
PMID:26141394 PMID:29079362 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of and results in decreased phosphorylation of GJA1 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of GJA1 protein]; SB 203580 inhibits the reaction [resveratrol results in increased expression of GJA1 protein] SB 203580 inhibits the reaction [fulvestrant promotes the reaction [NEDD4 protein binds to and results in increased ubiquitination of GJA1 protein]]; SB 203580 inhibits the reaction [fulvestrant results in decreased expression of GJA1 mRNA]; SB 203580 inhibits the reaction [fulvestrant results in decreased expression of GJA1 protein] SB 203580 inhibits the reaction [Phenylephrine results in increased expression of GJA1 mRNA]; SB 203580 inhibits the reaction [Phenylephrine results in increased expression of GJA1 protein] |
CTD |
PMID:18445782 PMID:23761298 PMID:24449132 PMID:27818224 PMID:29180066 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gjb1 |
gap junction protein, beta 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [1-methylanthracene affects the expression of and affects the activity of GJB1 protein]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] affects the expression of and affects the activity of GJB1 protein]; SB 203580 inhibits the reaction [fluoranthene affects the expression of and affects the activity of GJB1 protein] |
CTD |
PMID:28329830 |
|
NCBI chr X:66,501,848...66,509,783
Ensembl chr X:66,501,820...66,509,925
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
pyrazolanthrone promotes the reaction [SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]; SB 203580 promotes the reaction [pyrazolanthrone inhibits the reaction [Arsenic Trioxide results in increased activity of GLB1 protein]] |
CTD |
PMID:31734849 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Glul |
glutamate-ammonia ligase |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in decreased expression of GLUL protein] |
CTD |
PMID:24376630 |
|
NCBI chr13:65,969,053...66,035,121
Ensembl chr13:66,025,630...66,035,108
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[GMFB protein co-treated with Hydrogen Peroxide] results in increased abundance of Hydrogen Peroxide]; SB 203580 inhibits the reaction [[GMFB protein co-treated with Hydrogen Peroxide] results in increased activity of CASP3 protein] |
CTD |
PMID:12791701 |
|
NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein] |
CTD |
PMID:26218279 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Quercetin results in increased expression of GPX1 mRNA] |
CTD |
PMID:22197970 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gria2 |
glutamate ionotropic receptor AMPA type subunit 2 |
multiple interactions |
EXP |
SB 203580 affects the reaction [Sodium Glutamate affects the expression of GRIA2] |
CTD |
PMID:15139026 |
|
NCBI chr 2:165,949,379...166,069,510
Ensembl chr 2:165,947,521...166,069,510
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Paraquat results in increased cleavage of GSDMD protein] |
CTD |
PMID:38237652 |
|
NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions decreases activity |
ISO |
SB 203580 inhibits the reaction [DEFA1 protein results in increased phosphorylation of GSK3B protein]; SB 203580 inhibits the reaction [DEFA2 protein results in increased phosphorylation of GSK3B protein] SB 203580 results in decreased activity of GSK3B protein |
CTD |
PMID:10998351 PMID:19814765 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Quercetin results in increased expression of GSR mRNA] |
CTD |
PMID:22197970 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Quercetin results in increased expression of GSTP1 mRNA] |
CTD |
PMID:22197970 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Has2 |
hyaluronan synthase 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HAS2 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hbegf |
heparin-binding EGF-like growth factor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased expression of HBEGF mRNA]; SB 203580 inhibits the reaction [Sodium Chloride results in increased expression of HBEGF mRNA]; SB 203580 inhibits the reaction [vanadium pentoxide results in increased expression of HBEGF mRNA] |
CTD |
PMID:11159045 PMID:12676768 PMID:26800359 |
|
NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions decreases expression |
ISO |
[U 0126 co-treated with SB 203580] inhibits the reaction [[nickel sulfate co-treated with macrophage stimulatory lipopeptide 2] results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with Dinoprostone] results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased activity of HIF1A protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of HIF1A mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of and results in increased activity of and results in increased stability of HIF1A protein]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of and results in increased activity of HIF1A protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein] SB 203580 results in decreased expression of HIF1A protein |
CTD |
PMID:12482858 PMID:13679210 PMID:14695184 PMID:17082639 PMID:20152896 PMID:20600219 PMID:23526216 PMID:27297870 PMID:32890875 More...
|
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMGA2 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of HMGB1 protein] |
CTD |
PMID:27616297 |
|
NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565 Ensembl chr16:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions increases expression decreases expression |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Quercetin promotes the reaction [Ethanol results in increased activity of HMOX1 protein]]]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Quercetin results in increased activity of HMOX1 protein]; SB 203580 inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [2-butenal results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [2-butenal results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Cadmium results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [coniferaldehyde results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Curcumin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Dimethyl Fumarate results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [gallium nitrate results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Hemin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [kahweol results in increased expression of and results in increased activity of HMOX1 protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Plant Extracts results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Potassium Dichromate results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Quercetin promotes the reaction [Ethanol results in increased activity of HMOX1 protein]]; SB 203580 inhibits the reaction [Quercetin results in increased activity of HMOX1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Ritonavir results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Silver results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Simvastatin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Sulindac promotes the reaction [Arsenic Trioxide results in increased expression of HMOX1 protein]]; SB 203580 inhibits the reaction [tricarbonyldichlororuthenium (II) dimer results in increased expression of HMOX1 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin promotes the reaction [Ethanol results in increased activity of HMOX1 protein]]] SB 203580 results in increased expression of HMOX1 mRNA SB 203580 results in decreased expression of HMOX mRNA; SB 203580 results in decreased expression of HMOX1 mRNA SB 203580 inhibits the reaction [Ascorbic Acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [aureusidin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Methamphetamine results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Resveratrol results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Tropisetron results in increased expression of HMOX1 protein]; SB 203580 promotes the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of HMOX1 mRNA] SB 203580 inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [10-nitro-oleic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [17-hydroxyjolkinolide B promotes the reaction [Lipopolysaccharides results in increased expression of HMOX1 protein]]; SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [4-hydroxy-2-nonenal results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Copper results in increased expression of HMOX mRNA]; SB 203580 inhibits the reaction [Dieldrin results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [farrerol results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [hydroquinone results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Lead results in increased expression of HMOX mRNA]; SB 203580 inhibits the reaction [lipoteichoic acid results in increased expression of HMOX1 protein]; SB 203580 inhibits the reaction [Mercury results in increased expression of HMOX mRNA]; SB 203580 inhibits the reaction [Quercetin analog results in increased expression of HMOX1 mRNA]; SB 203580 inhibits the reaction [Quercetin results in increased expression of HMOX1 protein] |
CTD |
PMID:10874044 PMID:14647439 PMID:15504750 PMID:15770161 PMID:16171798 PMID:17433488 PMID:18078826 PMID:18332044 PMID:18357586 PMID:18586083 PMID:18636201 PMID:19576919 PMID:20594940 PMID:20961405 PMID:21192278 PMID:21238556 PMID:22036727 PMID:22056766 PMID:22080918 PMID:22488045 PMID:23022510 PMID:23285267 PMID:23290930 PMID:23500011 PMID:23845594 PMID:24140437 PMID:24211270 PMID:24376630 PMID:24423726 PMID:25881548 PMID:26111761 PMID:26275128 PMID:26385185 PMID:26404762 PMID:26542248 PMID:27454768 PMID:27777014 PMID:28087833 PMID:28329830 PMID:29796178 PMID:30040983 PMID:30626086 PMID:31029725 PMID:31306736 PMID:31790703 More...
|
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b1 |
hydroxysteroid 11-beta dehydrogenase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of HSD11B1 mRNA] |
CTD |
PMID:30993381 |
|
NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687
|
|
G |
Hsd17b3 |
hydroxysteroid (17-beta) dehydrogenase 3 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of HSD17B3 mRNA] |
CTD |
PMID:29567110 |
|
NCBI chr17:1,027,229...1,058,554
Ensembl chr17:1,027,229...1,058,554
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of HSF1 protein] |
CTD |
PMID:9822662 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of HSPA1B mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of HSPA5 protein]; SB 203580 inhibits the reaction [honokiol results in increased expression of HSPA5 protein]; SB 203580 inhibits the reaction [Indomethacin results in increased expression of HSPA5 protein] |
CTD |
PMID:17341418 PMID:33550458 PMID:34560123 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of HSPB1 protein] [SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of HSPB1 protein; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [lysophosphatidic acid results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of HSPB1 protein] SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of HSPB1 protein] SB 203580 results in decreased phosphorylation of HSPB1 protein |
CTD |
PMID:10903806 PMID:19100307 PMID:20864298 PMID:21457723 PMID:22000993 PMID:36049518 More...
|
|
NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
|
|
G |
Hspb2 |
heat shock protein family B (small) member 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Fluorouracil results in increased phosphorylation of HSPB2 protein] |
CTD |
PMID:18757417 |
|
NCBI chr 8:51,093,267...51,094,528
Ensembl chr 8:51,081,342...51,094,533
|
|
G |
Htr2a |
5-hydroxytryptamine receptor 2A |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Particulate Matter results in increased expression of HTR2A mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of HTR2A protein] |
CTD |
PMID:31199065 |
|
NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of ICAM1 protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [TNF results in increased expression of ICAM1 protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of ICAM1 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of ICAM1 protein] SB 203580 inhibits the reaction [resveratrol results in decreased expression of ICAM1 protein]; SB 203580 inhibits the reaction [tropisetron results in decreased expression of ICAM1 protein] |
CTD |
PMID:10792388 PMID:16582018 PMID:19020780 PMID:21192278 PMID:22226621 PMID:23285267 More...
|
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO EXP |
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased chemical synthesis of Nitrites]; [SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] results in decreased susceptibility to [IL1B protein co-treated with IFNG protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[IL12A protein binds to IL12B protein] which results in increased expression of IFNG protein]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [IFNG protein results in increased expression of CYP27B1 mRNA]; SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of CEBPB protein]; SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in decreased expression of IFNG protein] [SB 203580 co-treated with Manganese] inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]] SB 203580 inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein] |
CTD |
PMID:10903806 PMID:10952721 PMID:12911628 PMID:16307444 PMID:16355272 PMID:16488514 PMID:21295052 PMID:23831309 PMID:25352548 PMID:25766886 PMID:35006638 More...
|
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of and results in decreased secretion of IGF1 protein]] |
CTD |
PMID:26254549 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igf2 |
insulin-like growth factor 2 |
multiple interactions decreases response to substance |
ISO |
SB 203580 inhibits the reaction [IGF2 protein results in increased expression of STS mRNA] SB 203580 results in decreased susceptibility to IGF2 protein |
CTD |
PMID:24055520 |
|
NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of IKBKB protein] SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of IKBKB protein] |
CTD |
PMID:16765938 PMID:19616567 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of IL10 protein]; SB 203580 inhibits the reaction [nickel monoxide results in decreased expression of IL10 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Zymosan results in increased secretion of IL10 protein] SB 203580 inhibits the reaction [Folic Acid promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL10 protein]]; SB 203580 inhibits the reaction [Folic Acid results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL10 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 mRNA]; SB 203580 inhibits the reaction [morroniside results in increased expression of IL10 mRNA] |
CTD |
PMID:15894585 PMID:17698565 PMID:19100307 PMID:21135123 PMID:21586572 PMID:27738387 PMID:28235615 PMID:34867417 PMID:35006638 More...
|
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Formaldehyde results in increased expression of IL11 mRNA]; SB 203580 inhibits the reaction [Formaldehyde results in increased secretion of IL11 protein] |
CTD |
PMID:22138297 |
|
NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[IL12A protein binds to IL12B protein] which results in increased expression of IFNG protein]; SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of [IL12A protein binds to IL12B protein]]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]] SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL12A mRNA] |
CTD |
PMID:10952721 PMID:11006016 PMID:15894585 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of IL12B mRNA]; SB 203580 inhibits the reaction [[IL12A protein binds to IL12B protein] which results in increased expression of IFNG protein]; SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of [IL12A protein binds to IL12B protein]]; SB 203580 inhibits the reaction [Drugs, Chinese Herbal results in increased secretion of IL12B protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased secretion of IL12B protein]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of [IL12A protein binds to IL12B protein]]; SB 203580 inhibits the reaction [Polysaccharides results in increased secretion of IL12B protein] SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:10952721 PMID:11006016 PMID:15778123 PMID:15894585 PMID:19101624 PMID:20525893 PMID:33930529 More...
|
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
decreases expression |
ISO |
SB 203580 results in decreased expression of IL13RA2 mRNA |
CTD |
PMID:20660070 |
|
NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [IL17A protein promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of CXCL8 protein]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of IL6 protein] |
CTD |
PMID:12016129 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [IL18 protein results in increased expression of PTEN mRNA]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of and results in increased activity of RELA protein]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of ATF2 protein] |
CTD |
PMID:18215737 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [IL1A protein results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 protein] |
CTD |
PMID:14742690 PMID:15728660 PMID:16532021 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
ISO EXP |
[2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [[IL1B protein co-treated with IFNG protein] results in increased chemical synthesis of Nitrites]; [SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [IL1B protein results in increased chemical synthesis of Nitrites]; [SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] results in decreased susceptibility to [IL1B protein co-treated with IFNG protein]; SB 203580 affects the reaction [IL1B results in increased expression of CXCL8 protein]; SB 203580 analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; SB 203580 analog inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[IL1B protein co-treated with IL6 protein] results in increased expression of and results in increased secretion of CRP protein]; SB 203580 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [APP protein results in increased expression of and results in increased cleavage of IL1B protein]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [IL1B protein results in decreased expression of TNFRSF11B protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of CXCL8 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of F3 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of FOS mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of ELK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of FOS protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of HSPB1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased secretion of Dinoprostone]; SB 203580 inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [T-2 Toxin promotes the reaction [IL1B protein results in increased secretion of CXCL8 protein]]; SB 203580 promotes the reaction [bufalin results in increased expression of IL1B mRNA] SB 203580 results in decreased expression of IL1B protein SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Fungal Polysaccharides results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of IL1B protein]] SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein] results in increased activity of CASP3 protein]; SB 203580 inhibits the reaction [Acrolein results in increased cleavage of IL1B protein]; SB 203580 inhibits the reaction [Acrolein results in increased expression of and results in increased secretion of IL1B protein]; SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [CLDN2 protein results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of IL1B protein]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of IL1B mRNA]; SB 203580 inhibits the reaction [T-2 Toxin results in increased expression of IL1B mRNA] |
CTD |
PMID:10704466 PMID:10712238 PMID:10903806 PMID:11854442 PMID:15251176 PMID:15350541 PMID:17368305 PMID:17388968 PMID:18982426 PMID:19100307 PMID:19626664 PMID:19656660 PMID:20712904 PMID:21295052 PMID:21453744 PMID:22687552 PMID:22727857 PMID:22728154 PMID:23535185 PMID:25352548 PMID:25766886 PMID:26218279 PMID:26254549 PMID:27302421 PMID:27393034 PMID:27556861 PMID:28004443 PMID:28629242 PMID:29079362 PMID:31199065 PMID:31639409 PMID:35006638 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
SB 203580 affects the reaction [Methotrexate results in increased expression of IL2 protein]; SB 203580 inhibits the reaction [norcantharidin inhibits the reaction [[Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in increased secretion of IL2 protein]] |
CTD |
PMID:19100307 PMID:21075198 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il27 |
interleukin 27 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [nickel sulfate results in increased expression of IL27 mRNA] |
CTD |
PMID:30421605 |
|
NCBI chr 1:181,173,108...181,178,720
Ensembl chr 1:181,173,372...181,178,582
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Methadone results in increased expression of IL4 mRNA]; SB 203580 inhibits the reaction [Methotrexate results in decreased expression of IL4 protein]; SB 203580 inhibits the reaction [Morphine results in increased expression of IL4 mRNA] SB 203580 inhibits the reaction [dinitrophenyl-human serum albumin conjugate results in increased expression of IL4 mRNA]; SB 203580 promotes the reaction [dinitrophenyl-human serum albumin conjugate results in increased secretion of IL4 protein] |
CTD |
PMID:10611455 PMID:19100307 PMID:23965172 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases secretion decreases expression |
ISO EXP |
magnolin promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]]; magnolin promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein]]; SB 203580 affects the reaction [Methotrexate results in decreased expression of IL6 protein]; SB 203580 inhibits the reaction [7-ketocholesterol results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [[IL1B protein co-treated with IL6 protein] results in increased expression of and results in increased secretion of CRP protein]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with macrophage stimulatory lipopeptide 2] results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of and results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [doxifluridine results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [doxifluridine results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Fluorouracil results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [hexabromocyclododecane results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [IL17A protein promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [IL17A protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [IL1A protein results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [melamine results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [OSM protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [pentabromodiphenyl ether results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [tetrabromobisphenol A results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [Zymosan results in increased secretion of IL6 protein]; SB 203580 promotes the reaction [magnolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]]; SB 203580 promotes the reaction [magnolin inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein]]; SB 203580 results in decreased susceptibility to [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein] SB 203580 inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [Adenosine Triphosphate promotes the reaction [[Oleic Acid co-treated with Palmitic Acid] results in increased secretion of IL6 protein]]; SB 203580 inhibits the reaction [cobaltous chloride results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [diphenylarsinic acid results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Resveratrol results in decreased expression of IL6 protein]; SB 203580 inhibits the reaction [Tropisetron results in decreased expression of IL6 protein] SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Fungal Polysaccharides results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [Particulate Matter promotes the reaction [Tobacco Smoke Pollution results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution promotes the reaction [Particulate Matter results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution results in increased expression of IL6 mRNA] SB 203580 results in decreased secretion of IL6 protein SB 203580 results in decreased expression of IL6 protein |
CTD |
PMID:1970628 PMID:10704466 PMID:12016129 PMID:12794122 PMID:15251176 PMID:16424113 PMID:16532021 PMID:17196171 PMID:17388968 PMID:17698565 PMID:18457675 PMID:18515973 PMID:19100307 PMID:19101624 PMID:19371610 PMID:20143454 PMID:20307528 PMID:20600219 PMID:21192278 PMID:21548952 PMID:22036725 PMID:22178768 PMID:22472292 PMID:22727857 PMID:22728154 PMID:22915474 PMID:23285267 PMID:23535185 PMID:23624824 PMID:24184330 PMID:24376630 PMID:25348860 PMID:26718265 PMID:26763395 PMID:26862037 PMID:27295300 PMID:27920472 PMID:28087833 PMID:28235615 PMID:28329830 PMID:29906494 PMID:29979839 PMID:30919561 PMID:30993381 PMID:35006638 PMID:35122928 PMID:35147423 PMID:35499276 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [INS1 protein results in increased activity of MAPK14 protein] |
CTD |
PMID:8971075 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
[SB 203580 co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein] |
CTD |
PMID:11574405 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Insr |
insulin receptor |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [oleoylethanolamide affects the phosphorylation of and affects the activity of INSR protein] |
CTD |
PMID:19345745 |
|
NCBI chr12:1,193,193...1,330,976
Ensembl chr12:1,197,100...1,330,883
|
|
G |
Irgm |
immunity-related GTPase M |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of IRGM1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr10:33,233,513...33,241,594
Ensembl chr10:33,233,455...33,241,578
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [bisphenol A results in increased expression of IRS1 protein modified form] |
CTD |
PMID:29793316 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itga2 |
integrin subunit alpha 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of ITGA2 mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of ITGA2 mRNA]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of ITGA2 mRNA] |
CTD |
PMID:21635667 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of ITGAM protein]] |
CTD |
PMID:26254549 |
|
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb6 |
integrin subunit beta 6 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA] |
CTD |
PMID:21303922 |
|
NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of JUN protein]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of JUN mRNA] SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of JUN mRNA]; SB 203580 inhibits the reaction [Phenylephrine results in increased expression of JUN mRNA]; SB 203580 promotes the reaction [diphenylarsinic acid results in increased expression of and results in increased phosphorylation of JUN protein] SB 203580 inhibits the reaction [icariin results in increased expression of JUN protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of JUN protein] |
CTD |
PMID:11035063 PMID:15252869 PMID:18423597 PMID:19002563 PMID:19132243 PMID:21635667 PMID:28087833 More...
|
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein affects the localization of JUNB protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of JUNB mRNA] |
CTD |
PMID:21303922 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Methamphetamine results in increased expression of KCNB1 protein] |
CTD |
PMID:29297590 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kitlg |
KIT ligand |
decreases expression |
ISO |
SB 203580 results in decreased expression of SCF protein |
CTD |
PMID:15585325 |
|
NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214
|
|
G |
Klf4 |
KLF transcription factor 4 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF4 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602
|
|
G |
Klf5 |
KLF transcription factor 5 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of KLF5 mRNA] SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of KLF5 mRNA] |
CTD |
PMID:21712382 PMID:28329830 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf6 |
KLF transcription factor 6 |
multiple interactions |
ISO |
[Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA] |
CTD |
PMID:22486562 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Krt1 |
keratin 1 |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [Calcium results in increased expression of KRT1 mRNA]; SB 203580 inhibits the reaction [Calcium results in increased expression of KRT1 protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of KRT1 mRNA]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of KRT1 protein] SB 203580 results in decreased expression of KRT1 mRNA; SB 203580 results in decreased expression of KRT1 protein |
CTD |
PMID:21524694 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT18 protein] |
CTD |
PMID:22960429 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166 Ensembl chr10:133,157,475...133,161,166
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of KRT8 protein] |
CTD |
PMID:22960429 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
decreases activity |
ISO |
SB 203580 results in decreased activity of LCK protein |
CTD |
PMID:10998351 |
|
NCBI chr 5:141,888,318...141,916,945
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Lep |
leptin |
multiple interactions decreases response to substance |
ISO |
SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]]; SB 203580 inhibits the reaction [Vitamin K 3 results in increased expression of LEP mRNA] SB 203580 results in decreased susceptibility to LEP protein |
CTD |
PMID:16996477 PMID:19849856 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
affects response to substance |
ISO |
LEPR protein affects the susceptibility to SB 203580 |
CTD |
PMID:22933112 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Lif |
LIF, interleukin 6 family cytokine |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of LIF mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr14:79,131,049...79,140,486
Ensembl chr14:79,134,574...79,140,482
|
|
G |
Loricrin |
loricrin cornified envelope precursor protein |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [Calcium results in increased expression of LORICRIN mRNA]; SB 203580 inhibits the reaction [Calcium results in increased expression of LORICRIN protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of LORICRIN mRNA]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of LORICRIN protein] SB 203580 results in decreased expression of LORICRIN protein |
CTD |
PMID:21524694 |
|
NCBI chr 2:177,558,062...177,560,960
Ensembl chr 2:177,558,252...177,559,807
|
|
G |
Lrp1 |
LDL receptor related protein 1 |
multiple interactions increases expression |
ISO |
SB 203580 inhibits the reaction [tanshinone results in decreased expression of LRP1 mRNA] SB 203580 results in increased expression of LRP1 mRNA |
CTD |
PMID:21165580 |
|
NCBI chr 7:63,380,325...63,461,029
Ensembl chr 7:63,380,356...63,460,910
|
|
G |
Lta4h |
leukotriene A4 hydrolase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of LTA4H mRNA] |
CTD |
PMID:20382172 |
|
NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600
|
|
G |
Ltc4s |
leukotriene C4 synthase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of LTC4S mRNA] |
CTD |
PMID:20382172 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Lyz2 |
lysozyme 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [Heme analog results in increased secretion of LYZ protein] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
decreases expression |
EXP |
SB203580 decreases expression of protein in oxygen-glucose deprived rat neuronal PC12 cells |
RGD |
PMID:27769861 |
RGD:329853763 |
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO EXP |
SB 203580 promotes the reaction [sodium arsenite results in increased expression of and results in increased lipidation of MAP1LC3B protein] SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in decreased lipidation of MAP1LC3B protein]] |
CTD |
PMID:34861471 PMID:37769856 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690 Ensembl chr16:49,665,791...49,677,690
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
EXP ISO |
SB 203580 inhibits the reaction [MAP2K6 protein results in decreased expression of EP300 protein] SB 203580 inhibits the reaction [[MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] |
CTD |
PMID:15767673 PMID:27278863 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Map3k1 |
mitogen-activated protein kinase kinase kinase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[MAP3K1 gene mutant form results in increased activity of MAP3K1 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] |
CTD |
PMID:27278863 |
|
NCBI chr 2:43,348,572...43,414,706
Ensembl chr 2:43,350,098...43,414,463
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
[Temozolomide results in decreased susceptibility to Temozolomide] promotes the reaction [[thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK1 protein]; [thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK1 protein; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Dinitrochlorobenzene results in decreased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SB 203580 inhibits the reaction [honokiol results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; SB 203580 inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [bufalin results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK1 protein] SB 203580 results in increased phosphorylation of MAPK1 protein [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [esculetin results in increased phosphorylation of MAPK1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK1 protein] SB 203580 promotes the reaction [Anisomycin results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:9671412 PMID:10712238 PMID:10993886 PMID:12547826 PMID:15588916 PMID:17172471 PMID:17689939 PMID:18495191 PMID:21600278 PMID:22727857 PMID:26136938 PMID:27032576 PMID:28087833 PMID:30653946 PMID:33550458 PMID:36176197 More...
|
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk11 |
mitogen-activated protein kinase 11 |
multiple interactions decreases expression increases expression decreases activity |
ISO EXP |
Cadmium Chloride inhibits the reaction [SB 203580 results in decreased expression of MAPK11 mRNA]; Cadmium Chloride inhibits the reaction [SB 203580 results in increased expression of MAPK11 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of MAPK11 protein]; SB 203580 inhibits the reaction [MAPK11 protein results in increased phosphorylation of SOD2 protein] SB 203580 results in decreased activity of MAPK11 protein |
CTD |
PMID:10998351 PMID:19757093 PMID:24376630 PMID:24465521 |
|
NCBI chr 7:120,218,471...120,225,488
Ensembl chr 7:120,218,478...120,225,395
|
|
G |
Mapk12 |
mitogen-activated protein kinase 12 |
decreases expression |
ISO |
SB 203580 results in decreased expression of MAPK12 mRNA |
CTD |
PMID:19757093 |
|
NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664
|
|
G |
Mapk13 |
mitogen activated protein kinase 13 |
multiple interactions |
ISO |
[SB 203580 co-treated with Cadmium Chloride] results in increased expression of MAPK13 mRNA |
CTD |
PMID:19757093 |
|
NCBI chr20:6,835,277...6,845,500
Ensembl chr20:6,835,320...6,844,222
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions decreases activity |
ISO EXP |
MAPK14 protein mutant form inhibits the reaction [SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of EIF4E protein]]; SB 203580 inhibits the reaction [11,11'-dideoxyverticilin results in increased expression of and results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in decreased expression of MAPK14 mRNA]; SB 203580 inhibits the reaction [Cadmium results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [dracorhodin analog results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Geraniin results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [icaritin results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK14 protein]] [SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of MAPK14 protein; [SB 203580 results in decreased activity of MAPK14 protein] which results in decreased susceptibility to Doxorubicin; SB 203580 inhibits the reaction [[Methionine deficiency co-treated with Cysteine deficiency] results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of MAPK14 protein]; SB 203580 inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [INS1 protein results in increased activity of MAPK14 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in decreased phosphorylation of MAPK14 protein]]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPK14 protein]; SB 203580 promotes the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of MAPK14 protein] [SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of CAV1 protein]; [SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of PPARG protein alternative form]; SB 203580 affects the reaction [MAPK14 protein affects the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]]; SB 203580 inhibits the reaction [1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:8971075 PMID:9647221 PMID:10704466 PMID:10998351 PMID:11709198 PMID:12487375 PMID:12781867 PMID:14610070 PMID:14984747 PMID:15242773 PMID:15249425 PMID:15254963 PMID:15585325 PMID:15585369 PMID:15631803 PMID:15817653 PMID:15936597 PMID:15963507 PMID:15964311 PMID:16005925 PMID:16864444 PMID:19100307 PMID:19757093 PMID:19767766 PMID:20232314 PMID:21635667 PMID:22226621 PMID:24376630 PMID:27097871 PMID:28629242 PMID:29191728 PMID:36049518 PMID:37769856 PMID:38431053 More...
|
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
[Temozolomide results in decreased susceptibility to Temozolomide] promotes the reaction [[thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK3 protein]; [thymoquinone co-treated with SB 203580] results in increased phosphorylation of MAPK3 protein; SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in decreased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Dinitrochlorobenzene results in decreased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SB 203580 inhibits the reaction [honokiol results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Resveratrol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; SB 203580 inhibits the reaction [Thimerosal results in decreased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [bufalin results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK3 protein] SB 203580 results in increased phosphorylation of MAPK3 protein [Oxaliplatin co-treated with SB 203580] results in decreased phosphorylation of MAPK3 protein; [pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [esculetin results in increased phosphorylation of MAPK3 protein]; SB 203580 inhibits the reaction [Quercetin results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of MAPK3 protein] SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:10712238 PMID:10993886 PMID:12547826 PMID:15588916 PMID:17172471 PMID:17689939 PMID:18495191 PMID:19428505 PMID:21600278 PMID:22727857 PMID:26136938 PMID:27032576 PMID:28087833 PMID:30653946 PMID:33550458 PMID:36176197 More...
|
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation decreases activity |
EXP ISO |
SB 203580 promotes the reaction [Acrolein results in increased phosphorylation of MAPK8 protein] SB 203580 results in increased phosphorylation of MAPK8 protein SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased phosphorylation of MAPK8 protein]; SB 203580 inhibits the reaction [cinnamaldehyde results in increased phosphorylation of MAPK8 protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased activity of MAPK8 protein]; SB 203580 inhibits the reaction [polyhexamethyleneguanidine results in increased phosphorylation of MAPK8 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK8 protein]; SB 203580 promotes the reaction [nickel sulfate results in increased phosphorylation of MAPK8 protein] SB 203580 results in decreased activity of MAPK8 protein |
CTD |
PMID:12487375 PMID:13679210 PMID:15964311 PMID:16818652 PMID:18089842 PMID:18495191 PMID:28087833 PMID:30653946 PMID:30935901 More...
|
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [4-vinyl-2,6-dimethoxyphenol results in increased phosphorylation of MAPK9 protein]; SB 203580 promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK9 protein] |
CTD |
PMID:16818652 PMID:30653946 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapkapk2 |
MAPK activated protein kinase 2 |
multiple interactions increases phosphorylation decreases expression decreases phosphorylation |
ISO EXP |
SB 203580 inhibits the reaction [Arsenic Trioxide results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [arsenite results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [LY 303511 results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Methotrexate results in increased expression of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased phosphorylation of and results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Sodium Fluoride results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Sorbitol results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Tretinoin results in increased phosphorylation of MAPKAPK2 protein] SB 203580 results in increased phosphorylation of MAPKAPK2 protein SB 203580 results in decreased expression of MAPKAPK2 protein modified form SB 203580 inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein] SB 203580 affects the reaction [MAPK14 protein affects the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]]; SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Ethanol results in increased phosphorylation of MAPKAPK2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK2 protein]; SB 203580 inhibits the reaction [trovafloxacin results in increased phosphorylation of MAPKAPK2 protein] SB 203580 results in decreased phosphorylation of MAPKAPK2 protein |
CTD |
PMID:9288946 PMID:9545260 PMID:9822662 PMID:9877156 PMID:10704466 PMID:12239215 PMID:12547826 PMID:14511371 PMID:15362974 PMID:16431125 PMID:18476811 PMID:19100307 PMID:19376214 PMID:21135123 PMID:21219922 PMID:23851002 PMID:24176848 PMID:24525298 PMID:27270636 PMID:28329830 PMID:30709899 More...
|
|
NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
|
|
G |
Mapkapk3 |
MAPK activated protein kinase 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [sodium arsenite results in increased activity of MAPKAPK3 protein] |
CTD |
PMID:12547826 |
|
NCBI chr 8:107,929,754...107,963,638
Ensembl chr 8:107,929,762...107,963,568
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of MAPT protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein] SB 203580 inhibits the reaction [cyanoginosin LR results in increased localization of MAPT protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of MAPT protein] |
CTD |
PMID:12605413 PMID:22000993 PMID:23929704 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [icariin affects the localization of MEF2C protein]; SB 203580 inhibits the reaction [icariin results in increased expression of MEF2C mRNA] |
CTD |
PMID:18423597 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Mgmt |
O-6-methylguanine-DNA methyltransferase |
decreases expression multiple interactions |
ISO |
SB 203580 results in decreased expression of MGMT protein [[Temozolomide results in decreased susceptibility to Temozolomide] which results in increased susceptibility to SB 203580] which results in increased expression of MGMT protein; [Temozolomide results in decreased susceptibility to Temozolomide] inhibits the reaction [SB 203580 results in decreased expression of MGMT protein] |
CTD |
PMID:36176197 |
|
NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
|
|
G |
Mir143 |
microRNA 143 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR143] |
CTD |
PMID:21712382 |
|
NCBI chr18:55,101,006...55,101,110
Ensembl chr18:55,101,006...55,101,110
|
|
G |
Mir145 |
microRNA 145 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR145] |
CTD |
PMID:21712382 |
|
NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727
|
|
G |
Mir328 |
microRNA 328 |
increases expression multiple interactions |
ISO |
SB 203580 results in increased expression of MIR328 mRNA resveratrol promotes the reaction [SB 203580 results in increased expression of MIR328 mRNA] |
CTD |
PMID:25605016 |
|
NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849
|
|
G |
Mitf |
melanocyte inducing transcription factor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cannabidiol results in increased expression of MITF mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
|
|
G |
Mknk1 |
MAPK interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MKNK1 protein]]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MKNK1 protein]; SB 203580 inhibits the reaction [Anisomycin results in increased activity of MKNK1 protein]; SB 203580 inhibits the reaction [arsenite results in increased activity of MKNK1 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MKNK1 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MKNK1 protein]] [SB 203580 co-treated with U 0126] inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MKNK1 protein] |
CTD |
PMID:9545260 PMID:12781867 PMID:16431125 |
|
NCBI chr 5:129,318,128...129,357,641
Ensembl chr 5:129,318,170...129,357,639
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [2-(1'H-indole-3'-carbonyl)thiazole-4-carboxylic acid methyl ester results in increased expression of and results in increased activity of MMP1 protein]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of MMP1 mRNA]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of and results in increased activity of MMP1 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP1 protein] |
CTD |
PMID:20004183 PMID:21635667 PMID:24469321 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
multiple interactions |
ISO EXP |
SB 203580 analog inhibits the reaction [IL1B results in increased expression of MMP13 mRNA]; SB 203580 inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP13 protein] SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of MMP13 mRNA] SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP13 mRNA]; SB 203580 inhibits the reaction [halofuginone results in increased expression of MMP13 mRNA] |
CTD |
PMID:12493575 PMID:16489207 PMID:16948116 PMID:19656660 PMID:20004183 PMID:28329830 More...
|
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions affects expression decreases expression |
ISO EXP |
brazilein promotes the reaction [SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein]; SB 203580 affects the reaction [U 0126 promotes the reaction [Plant Extracts results in decreased expression of MMP2 protein]]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Air Pollutants results in increased activity of MMP2 protein]]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Particulate Matter results in increased activity of MMP2 protein]]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [taiwanin E results in decreased expression of MMP2 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP2 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP2 mRNA]; SB 203580 promotes the reaction [brazilein results in decreased expression of and results in decreased activity of MMP2 protein]; SB 203580 promotes the reaction [resveratrol results in decreased expression of and results in decreased activity of MMP2 protein]; SB 203580 promotes the reaction [resveratrol results in decreased expression of MMP2]; SB 203580 results in decreased expression of and results in decreased activity of MMP2 protein SB 203580 affects the expression of MMP2 mRNA; SB 203580 affects the expression of MMP2 protein SB 203580 results in decreased expression of MMP2 |
CTD |
PMID:16575906 PMID:20599481 PMID:21635667 PMID:23707804 PMID:24841706 PMID:24929186 PMID:25605016 PMID:26179980 PMID:27807932 PMID:28181379 More...
|
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp25 |
matrix metallopeptidase 25 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of MMP25 mRNA] |
CTD |
PMID:21635667 |
|
NCBI chr10:12,661,297...12,676,119
Ensembl chr10:12,661,208...12,675,871
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MMP3 protein] |
CTD |
PMID:20004183 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression decreases activity |
ISO EXP |
[kahweol acetate co-treated with SB 203580] inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [FSL-1 lipoprotein, synthetic results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Air Pollutants results in increased activity of MMP9 protein]]; SB 203580 inhibits the reaction [Glucose promotes the reaction [Particulate Matter results in increased activity of MMP9 protein]]; SB 203580 inhibits the reaction [hydroquinone results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [taiwanin E results in decreased expression of MMP9 protein]; SB 203580 inhibits the reaction [tetrabromobisphenol A results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein]; SB 203580 inhibits the reaction [thymoquinone results in decreased expression of MMP9 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; SB 203580 promotes the reaction [3,5-bis(2-fluorobenzylidene)piperidin-4-one inhibits the reaction [Tetradecanoylphorbol Acetate results in increased activity of MMP9 protein]]; SB 203580 promotes the reaction [ovatodiolide results in decreased activity of MMP9 protein]; SB 203580 promotes the reaction [Resveratrol results in decreased expression of MMP9]; SB 203580 promotes the reaction [Resveratrol results in increased expression of and results in increased activity of MMP9 protein] SB 203580 results in decreased expression of MMP9 mRNA; SB 203580 results in decreased expression of MMP9 protein SB 203580 results in decreased activity of MMP9 protein SB 203580 inhibits the reaction [Doxorubicin results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [Doxorubicin results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [gadolinium chloride results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [T-2 Toxin results in increased expression of MMP9 mRNA]; SB 203580 promotes the reaction [U 0126 inhibits the reaction [Lipopolysaccharides results in increased activity of MMP9 protein]]; U 0126 promotes the reaction [SB 203580 inhibits the reaction [Lipopolysaccharides results in increased activity of MMP9 protein]] SB 203580 inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in increased expression of MMP9 protein] |
CTD |
PMID:12493575 PMID:15657063 PMID:15728660 PMID:16213474 PMID:16683234 PMID:19837106 PMID:19962414 PMID:20152819 PMID:21354279 PMID:22033475 PMID:22705379 PMID:23229870 PMID:24841706 PMID:25200491 PMID:26179980 PMID:26807887 PMID:27060453 PMID:27807932 PMID:27818224 PMID:27829220 PMID:29079362 PMID:30590137 PMID:30766661 PMID:30801954 PMID:36413041 More...
|
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions decreases activity |
EXP ISO |
SB 203580 inhibits the reaction [Resveratrol results in decreased activity of MPO protein]; SB 203580 inhibits the reaction [Tropisetron results in decreased activity of MPO protein] SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased activity of MPO protein] SB 203580 results in decreased activity of MPO protein |
CTD |
PMID:17368305 PMID:21192278 PMID:23285267 PMID:27920472 PMID:32033504 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt1 |
metallothionein 1 |
multiple interactions |
ISO |
SB 203580 promotes the reaction [Copper results in increased activity of MT1 promoter] |
CTD |
PMID:14576086 |
|
NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049 Ensembl chr17:10,826,032...10,827,049 Ensembl chr X:10,826,032...10,827,049
|
|
G |
Mt3 |
metallothionein 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cadmium results in increased expression of MT3] |
CTD |
PMID:21783819 |
|
NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158
|
|
G |
Mtmr10 |
myotubularin related protein 10 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of MTMR10 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 1:117,859,355...117,910,839
Ensembl chr 1:117,859,267...117,910,849
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [fenvalerate results in decreased phosphorylation of MTOR protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased phosphorylation of MTOR protein]] |
CTD |
PMID:31734597 PMID:37769856 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc4 |
mucin 4, cell surface associated |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Particulate Matter results in increased expression of MUC4 mRNA]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of MUC4 protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of MUC4 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of MUC4 protein] |
CTD |
PMID:28049186 |
|
NCBI chr11:68,008,245...68,053,242
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [EGF protein results in increased secretion of MUC5AC protein]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of MUC5AC mRNA]; SB 203580 inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC mRNA]; SB 203580 inhibits the reaction [polyhexamethyleneguanidine results in increased expression of MUC5AC protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MUC5AC mRNA] |
CTD |
PMID:20971882 PMID:22766066 PMID:30935901 PMID:34167450 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Myh7 |
myosin heavy chain 7 |
affects expression |
EXP |
SB 203580 affects the expression of MYH7 mRNA |
CTD |
PMID:21084678 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Myocd |
myocardin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MYOCD mRNA] |
CTD |
PMID:21712382 |
|
NCBI chr10:49,833,219...49,928,806
Ensembl chr10:49,836,641...49,927,627
|
|
G |
Myod1 |
myogenic differentiation 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [bakuchiol results in increased expression of MYOD1 protein] |
CTD |
PMID:26902638 |
|
NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
|
|
G |
Myog |
myogenin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [bakuchiol results in increased expression of MYOG protein] |
CTD |
PMID:26902638 |
|
NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [arsenic trioxide results in increased phosphorylation of and affects the localization of NCF1 protein] |
CTD |
PMID:18424721 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nedd4 |
NEDD4 E3 ubiquitin protein ligase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [fulvestrant promotes the reaction [NEDD4 protein binds to and results in increased ubiquitination of GJA1 protein]] |
CTD |
PMID:29180066 |
|
NCBI chr 8:73,384,095...73,468,951
Ensembl chr 8:73,383,695...73,468,951
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
multiple interactions |
ISO |
SB 203580 affects the reaction [NFE2L2 protein affects the reaction [sodium arsenite affects the expression of NFATC1 protein]]; SB 203580 affects the reaction [sodium arsenite affects the expression of NFATC1 protein] |
CTD |
PMID:30742845 |
|
NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Quercetin affects the localization of NFE2L2 protein]]; [SB 203580 co-treated with Cycloheximide] inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; [SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein; Cycloheximide inhibits the reaction [[SB 203580 co-treated with Quercetin] results in increased expression of NFE2L2 protein]; Cycloheximide inhibits the reaction [SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]]; SB 203580 affects the reaction [Quercetin affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [gallium nitrate results in increased activity of NFE2L2 protein]; SB 203580 inhibits the reaction [Quercetin affects the localization of and results in increased activity of NFE2L2 protein]; SB 203580 inhibits the reaction [Quercetin affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [Quercetin results in decreased expression of NFE2L2 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Quercetin affects the localization of NFE2L2 protein]] SB 203580 inhibits the reaction [aureusidin affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [Chitosan analog inhibits the reaction [Doxorubicin affects the localization of NFE2L2 protein]]; SB 203580 inhibits the reaction [Curcumin affects the localization of NFE2L2 protein] SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 affects the reaction [NFE2L2 protein affects the reaction [sodium arsenite affects the expression of NFATC1 protein]]; SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone affects the localization of NFE2L2 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased expression of NFE2L2 mRNA]; SB 203580 inhibits the reaction [farrerol affects the localization of NFE2L2 protein]; SB 203580 promotes the reaction [[Plant Extracts co-treated with Ethanol] results in increased expression of and affects the localization of NFE2L2 protein] |
CTD |
PMID:17433488 PMID:17640564 PMID:18586083 PMID:22197970 PMID:22488045 PMID:25449124 PMID:26111761 PMID:27454768 PMID:30742845 PMID:30928397 PMID:31029725 PMID:31790703 More...
|
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Paraquat affects the localization of [NFKB1 protein binds to RELA protein]]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli affects the localization of [NFKB1 protein binds to RELA protein]]] SB 203580 inhibits the reaction [indoleacetic acid affects the localization of NFKB1 protein] |
CTD |
PMID:16919916 PMID:30324315 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions decreases expression |
ISO EXP |
SB 203580 inhibits the reaction [icariin results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] SB 203580 results in decreased expression of NFKBIA protein SB 203580 promotes the reaction [ferrous sulfate results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [Iron results in increased phosphorylation of NFKBIA protein] SB 203580 inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in increased expression of NFKBIA protein]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:17172471 PMID:18423597 PMID:19132243 PMID:23707484 PMID:33030807 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Ngf |
nerve growth factor |
multiple interactions decreases activity |
EXP |
SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF mRNA]; SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGF protein] SB 203580 results in decreased activity of NGF protein |
CTD |
PMID:9733710 PMID:17651887 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Ngfr |
nerve growth factor receptor |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR mRNA]; SB 203580 inhibits the reaction [pentaacetyl geniposide results in increased expression of NGFR protein] |
CTD |
PMID:17651887 |
|
NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of NLRP3 protein]; SB 203580 inhibits the reaction [APP protein results in increased expression of NLRP3 protein] SB 203580 inhibits the reaction [Acrolein results in increased expression of NLRP3 protein] |
CTD |
PMID:28004443 PMID:31639409 PMID:34510229 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions decreases expression increases degradation |
ISO EXP |
SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of NOS2 protein] SB 203580 results in decreased expression of NOS2 mRNA; SB 203580 results in decreased expression of NOS2 protein SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Antimony Potassium Tartrate results in increased abundance of Antimony] which results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of NOS2 mRNA]]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of NOS2 mRNA] SB 203580 results in increased degradation of NOS2 mRNA 1-dodecylsulfonyl-5N,6O-oxomethylidenenojirimycin promotes the reaction [SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitric Oxide]; SB 203580 inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide]; SB 203580 inhibits the reaction [[trimethyltin chloride results in increased abundance of trimethyltin] which results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [lipoteichoic acid results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [Methoxychlor results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 protein]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOS2 protein]] |
CTD |
PMID:11518563 PMID:12911628 PMID:14734799 PMID:15979571 PMID:16307444 PMID:16376947 PMID:16488514 PMID:17368305 PMID:20004183 PMID:20712904 PMID:22227475 PMID:23268108 PMID:23500011 PMID:23624824 PMID:23727179 PMID:23735482 PMID:25352548 PMID:25766886 PMID:26218279 PMID:26254549 PMID:29191728 PMID:30993381 PMID:31199065 PMID:34571074 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of NOS3 protein] |
CTD |
PMID:11788791 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [o,p'-DDT results in increased activity of NOTCH1 protein] |
CTD |
PMID:18791200 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Lead results in increased expression of NOX1 mRNA]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of NOX1 mRNA] |
CTD |
PMID:23415682 PMID:25596430 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Lead results in increased expression of NOX4 mRNA] |
CTD |
PMID:25596430 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nppa |
natriuretic peptide A |
affects secretion multiple interactions |
EXP |
SB 203580 affects the secretion of NPPA protein SB203580 increases expression of mRNA and potentiates the reaction [sunitinib increases expression of mRNA] in rat cardiomyocytes SB 203580 inhibits the reaction [Phenylephrine results in increased expression of NPPA mRNA]; SB 203580 promotes the reaction [Sunitinib results in increased expression of NPPA mRNA] |
CTD RGD |
PMID:10727428 PMID:21084678 PMID:24247421 PMID:24247421 |
RGD:401793741 |
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
affects expression decreases expression multiple interactions |
EXP |
SB 203580 affects the expression of NPPB protein SB 203580 results in decreased expression of NPPB mRNA SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of NPPB protein] |
CTD |
PMID:21084678 PMID:22224641 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [Particulate Matter analog results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [Particulate Matter analog results in increased expression of NQO1 protein]; SB 203580 inhibits the reaction [Plant Extracts results in increased expression of NQO1 protein]; SB 203580 inhibits the reaction [Quercetin results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [Vehicle Emissions analog results in increased expression of NQO1 protein] SB 203580 inhibits the reaction [2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone results in increased expression of NQO1 mRNA]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of NQO1 mRNA]; SB 203580 promotes the reaction [Copper results in increased expression of NQO1 mRNA]; SB 203580 promotes the reaction [Lead results in increased expression of NQO1 mRNA] SB 203580 results in decreased expression of NQO1 mRNA |
CTD |
PMID:16920990 PMID:18752316 PMID:27454768 PMID:28329830 PMID:30626086 PMID:31029725 More...
|
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
ISO |
SB 203580 results in increased expression of NR1H3 mRNA |
CTD |
PMID:19883121 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [deacylcortivazol results in increased phosphorylation of NR3C1 protein]; SB 203580 inhibits the reaction [Dexamethasone results in increased phosphorylation of NR3C1 protein] |
CTD |
PMID:15817653 |
|
NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of NR4A1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Ocln |
occludin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Arsenic Trioxide results in decreased expression of OCLN protein]; SB 203580 inhibits the reaction [Clopidogrel results in decreased expression of OCLN protein] SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of OCLN protein] |
CTD |
PMID:23220562 PMID:23761298 PMID:27818224 PMID:32683294 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Olr1 |
oxidized low density lipoprotein receptor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of OLR1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of OSGIN1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
Osm |
oncostatin M |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [OSM protein results in increased expression of and results in increased secretion of IL6 protein]; SB 203580 inhibits the reaction [OSM protein results in increased expression of IL6 mRNA] |
CTD |
PMID:21548952 |
|
NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
ISO |
SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of Dinoprostone]]; SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]] |
CTD |
PMID:26691871 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [3-oxo-29-noroleana-1,9(11),12-trien-2,20-dicarbonitrile results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR1 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Estradiol] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [[ESR2 protein results in increased susceptibility to Quercetin] which results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Arsenic Trioxide results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [CSC-3436 promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; SB 203580 inhibits the reaction [Doxorubicin results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Emodin results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [isoliensinine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [scutebarbatine A results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Tamoxifen results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [TNFSF10 protein promotes the reaction [CSC-3436 results in increased cleavage of PARP1 protein]]; SB 203580 promotes the reaction [[sodium arsenite co-treated with TNF protein] results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [luteolin-7-glucoside results in increased cleavage of PARP1 protein] |
CTD |
PMID:14645110 PMID:16328441 PMID:16843435 PMID:19194971 PMID:19777565 PMID:21732360 PMID:24036456 PMID:25446857 PMID:26219228 PMID:27032576 PMID:29479036 PMID:30871965 PMID:32890875 PMID:34165247 PMID:34599545 PMID:37072049 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Buthionine Sulfoximine results in increased expression of PCK1 mRNA] |
CTD |
PMID:16960379 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]] |
CTD |
PMID:32890875 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[IL1A co-treated with PDGFB] results in increased secretion of MMP9 protein]; SB 203580 results in decreased susceptibility to [PDGFB protein binds to PDGFB protein] SB 203580 promotes the reaction [PDGFB protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:9671412 PMID:15728660 PMID:23457620 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdx1 |
pancreatic and duodenal homeobox 1 |
multiple interactions |
ISO |
[SB 203580 co-treated with INS protein] inhibits the reaction [Glucose affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [[Glucose co-treated with sodium arsenite] affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [Glucose affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [Glucose results in increased phosphorylation of and results in increased activity of PDX1 protein]; SB 203580 inhibits the reaction [sodium arsenite affects the localization of PDX1 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of PDX1 protein] |
CTD |
PMID:9873045 PMID:11574405 |
|
NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PHLDA1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [Capsaicin results in increased phosphorylation of PLA2G4A protein] SB 203580 inhibits the reaction [Hydrogen Peroxide results in decreased expression of PLA2G4A mRNA] |
CTD |
PMID:15683734 PMID:19959817 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PLA2G7 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of PLA2G7 protein] |
CTD |
PMID:21176638 PMID:21432021 |
|
NCBI chr 9:17,362,214...17,404,476
Ensembl chr 9:17,362,225...17,404,476
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PLAUR mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 1:80,053,440...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Pld1 |
phospholipase D1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased expression of PLD1 mRNA]; SB 203580 inhibits the reaction [Tobacco Smoke Pollution analog results in increased phosphorylation of PLD1 protein] |
CTD |
PMID:26763395 |
|
NCBI chr 2:110,849,205...111,047,304
Ensembl chr 2:110,893,608...111,047,692
|
|
G |
Pld2 |
phospholipase D2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]] |
CTD |
PMID:15210717 |
|
NCBI chr10:55,256,326...55,274,192
Ensembl chr10:55,256,359...55,272,808
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [POMC protein modified form results in increased secretion of Corticosterone] |
CTD |
PMID:20837582 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Postn |
periostin |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [AGT protein results in increased expression of POSTN mRNA]; SB 203580 inhibits the reaction [FGF1 protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 PMID:17485602 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [(1R,3S,3aR,8bS)-3a-(4-Bromophenyl)-6,8-dimethoxy-3-phenyl-2,3,3a,8b-tetrahydro-1H-cyclopenta(b)benzofuran-1,8b-diol results in decreased expression of POU5F1 protein] |
CTD |
PMID:24607276 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Indomethacin results in increased expression of PPARD protein] |
CTD |
PMID:17341418 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions increases expression decreases expression |
ISO EXP |
[SB 203580 results in decreased activity of MAPK14 protein] inhibits the reaction [[octanoic acid co-treated with Dexamethasone] results in increased expression of PPARG protein alternative form] SB 203580 inhibits the reaction [Ethanol results in decreased expression of PPARG protein] SB 203580 results in increased expression of PPARG mRNA; SB 203580 results in increased expression of PPARG protein SB 203580 results in decreased expression of PPARG mRNA; SB 203580 results in decreased expression of PPARG protein |
CTD |
PMID:14984747 PMID:23603106 PMID:24412557 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Pram1 |
PML-RARA regulated adaptor molecule 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of PRAM1 protein] |
CTD |
PMID:12508112 |
|
NCBI chr 7:14,428,548...14,438,081
Ensembl chr 7:14,420,165...14,438,166
|
|
G |
Prdx1 |
peroxiredoxin 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [sodium arsenate results in increased expression of PRDX1 protein] |
CTD |
PMID:11796722 |
|
NCBI chr 5:130,147,258...130,162,856
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prdx2 |
peroxiredoxin 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Formaldehyde results in decreased expression of PRDX2 protein] |
CTD |
PMID:20347000 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
ISO |
[SB 203580 co-treated with Quercetin] results in increased phosphorylation of PRKAA1 protein |
CTD |
PMID:24535669 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Procr |
protein C receptor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in decreased cleavage of PROCR protein] |
CTD |
PMID:24632454 |
|
NCBI chr 3:144,254,596...144,258,863
Ensembl chr 3:144,254,380...144,258,903
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Pten |
phosphatase and tensin homolog |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [IL18 protein results in increased expression of PTEN mRNA] |
CTD |
PMID:18215737 |
|
NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgds |
prostaglandin D2 synthase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGDS mRNA] |
CTD |
PMID:20382172 |
|
NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:8,281,899...8,284,833
|
|
G |
Ptges2 |
prostaglandin E synthase 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGES2 mRNA] |
CTD |
PMID:20382172 |
|
NCBI chr 3:15,690,501...15,697,688
Ensembl chr 3:15,690,501...15,697,688
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
ISO EXP |
SB 203580 analog inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased activity of PTGS2 protein]; SB 203580 inhibits the reaction [[methanandamide results in increased expression of PTGS2 mRNA] which results in increased chemical synthesis of Dinoprostone]; SB 203580 inhibits the reaction [[nickel sulfate co-treated with macrophage stimulatory lipopeptide 2] results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Aflatoxin B1 results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Aspirin results in decreased degradation of PTGS2 mRNA]; SB 203580 inhibits the reaction [Aspirin results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Aspirin results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Benzene results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Ceramides results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Chlorpyrifos results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [IL1A results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1B protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [IL1B results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Melitten results in decreased expression of PTGS2 protein]; SB 203580 inhibits the reaction [methanandamide results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [methylmercuric chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [PLD2 protein promotes the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Sodium Fluoride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Styrene results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Toluene results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Zinc results in increased expression of PTGS2 protein] SB 203580 inhibits the reaction [[IFNG protein co-treated with Lipopolysaccharides] results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [cadmium sulfate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [epigallocatechin gallate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [lead acetate results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lead results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [manganese chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Serotonin results in increased expression of PTGS2 mRNA] SB 203580 results in decreased expression of PTGS2 mRNA; SB 203580 results in decreased expression of PTGS2 protein SB 203580 inhibits the reaction [1-bromopropane results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [2-chloroethyl ethyl sulfide results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 mRNA] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [[Cadmium Chloride results in increased expression of PTGS2 protein] which results in increased abundance of Dinoprostone]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased stability of PTGS2 mRNA]; SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [lipoteichoic acid results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Nickel results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [nonylphenol results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [o,p'-DDT results in increased expression of PTGS2 protein] |
CTD |
PMID:11527419 PMID:11854442 PMID:12377986 PMID:12911628 PMID:14742690 PMID:15210717 PMID:15980035 PMID:16330497 PMID:16765938 PMID:16777358 PMID:17084486 PMID:17368305 PMID:17767925 PMID:18457675 PMID:18596194 PMID:18805435 PMID:18840457 PMID:19084589 PMID:19145780 PMID:19376214 PMID:19656660 PMID:19839048 PMID:20004183 PMID:20382172 PMID:20600219 PMID:20954072 PMID:21262218 PMID:21801798 PMID:22353212 PMID:22728154 PMID:22767315 PMID:23110475 PMID:23268108 PMID:23376440 PMID:23415682 PMID:23416140 PMID:23495037 PMID:23500011 PMID:23690655 PMID:23727179 PMID:23735482 PMID:23968725 PMID:24961358 PMID:25596430 PMID:26218279 PMID:26691871 PMID:27818125 PMID:28329830 PMID:28958600 PMID:32890875 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptx3 |
pentraxin 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of PTX3 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:150,487,513...150,493,323
|
|
G |
Rad51 |
RAD51 recombinase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [ochratoxin A results in decreased expression of RAD51]; SB 203580 inhibits the reaction [Prodigiosin results in decreased expression of RAD51 mRNA] |
CTD |
PMID:22579953 PMID:24525463 |
|
NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [FGF2 protein results in increased phosphorylation of RB1 protein] |
CTD |
PMID:15249425 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbm4 |
RNA binding motif protein 4 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [sodium arsenite affects the localization of RBM4 protein] |
CTD |
PMID:17284590 |
|
NCBI chr 1:202,078,442...202,087,506
Ensembl chr 1:202,085,279...202,105,380
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
multiple interactions |
ISO |
[PSEN1 protein affects the susceptibility to SB 203580] affects the reaction [Cycloheximide results in decreased expression of RBPJ protein] |
CTD |
PMID:22302987 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [AGT protein results in increased expression of REG3G mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of REG3G mRNA] |
CTD |
PMID:27798352 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
SB 203580 affects the reaction [sodium arsenite affects the expression of RELA protein]; SB 203580 inhibits the reaction [[Iron-Dextran Complex results in increased abundance of Iron] which affects the localization of RELA protein]; SB 203580 inhibits the reaction [benzyloxycarbonylleucyl-leucyl-leucine aldehyde results in increased activity of RELA protein]; SB 203580 inhibits the reaction [chrysin results in increased activity of RELA protein]; SB 203580 inhibits the reaction [deoxynivalenol results in increased activity of RELA protein]; SB 203580 inhibits the reaction [ferruginol results in increased expression of RELA protein]; SB 203580 inhibits the reaction [Galactose affects the localization of RELA protein]; SB 203580 inhibits the reaction [IL18 protein results in increased phosphorylation of and results in increased activity of RELA protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased phosphorylation of RELA protein]; SB 203580 inhibits the reaction [Paraquat results in increased phosphorylation of RELA protein]; SB 203580 inhibits the reaction [vanadyl sulfate results in increased activity of RELA protein] SB 203580 inhibits the reaction [Acrolein results in increased phosphorylation of RELA protein]; SB 203580 inhibits the reaction [Cyclosporine affects the localization of RELA protein]; SB 203580 inhibits the reaction [Lipopolysaccharides affects the localization of RELA protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of RELA protein] SB 203580 inhibits the reaction [endotoxin, Escherichia coli results in increased activity of RELA protein]; SB 203580 inhibits the reaction [icariin results in increased expression of and affects the localization of RELA protein]; SB 203580 inhibits the reaction [Paraquat affects the localization of [NFKB1 protein binds to RELA protein]]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli affects the localization of [NFKB1 protein binds to RELA protein]]] |
CTD |
PMID:10873158 PMID:16919916 PMID:18215737 PMID:18423597 PMID:18457675 PMID:18599499 PMID:19616567 PMID:20885979 PMID:22036725 PMID:23755222 PMID:25772258 PMID:29412148 PMID:29528074 PMID:30086653 PMID:31639409 PMID:33285147 PMID:38237652 More...
|
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rest |
RE1-silencing transcription factor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Sodium Glutamate results in increased expression of REST mRNA] |
CTD |
PMID:16782274 |
|
NCBI chr14:30,859,109...30,879,828
Ensembl chr14:30,862,553...30,894,354
|
|
G |
Retn |
resistin |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [octylphenol results in increased expression of RETN protein] SB 203580 results in decreased expression of RETN protein |
CTD |
PMID:18417718 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Rnd3 |
Rho family GTPase 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of RND3 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 3:35,571,929...35,589,283
Ensembl chr 3:35,571,143...35,589,327
|
|
G |
Rps6ka5 |
ribosomal protein S6 kinase A5 |
multiple interactions |
ISO EXP |
[U 0126 co-treated with SB 203580] inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased activity of RPS6KA5 protein] SB 203580 inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of RPS6KA5 protein] |
CTD |
PMID:12547826 PMID:15522277 |
|
NCBI chr 6:119,828,823...120,006,190
Ensembl chr 6:119,828,846...120,006,224
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]; Sodium Salicylate inhibits the reaction [SB 203580 promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of and results in increased activity of RPS6KB1 protein]] |
CTD |
PMID:10993886 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
[pyrazolanthrone co-treated with SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Quercetin results in increased expression of RUNX2 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of RUNX2 mRNA] |
CTD |
PMID:26136938 PMID:31472278 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [S100A4 protein results in increased expression of MMP13 protein] |
CTD |
PMID:16948116 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
S100b |
S100 calcium binding protein B |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [S100B protein results in increased expression of NOS2 protein] |
CTD |
PMID:16376947 |
|
NCBI chr20:12,372,866...12,381,619
Ensembl chr20:12,372,881...12,394,743
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of SELE mRNA] |
CTD |
PMID:16582018 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Serpinb2 |
serpin family B member 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SERPINB2 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [cupric oxide results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:20171267 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpinh1 |
serpin family H member 1 |
decreases expression multiple interactions |
ISO |
SB 203580 results in decreased expression of SERPINH1 mRNA SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of SERPINH1 mRNA] |
CTD |
PMID:13679210 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Sesn2 |
sestrin 2 |
multiple interactions |
ISO |
[SB 203580 co-treated with Quercetin] results in increased expression of SESN2 protein |
CTD |
PMID:24535669 |
|
NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Hydrogen Peroxide affects the localization of SIRT1 protein] SB 203580 inhibits the reaction [icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 mRNA]]; SB 203580 inhibits the reaction [icariin promotes the reaction [[Oxygen deficiency co-treated with Glucose deficiency] results in increased expression of SIRT1 protein]] |
CTD |
PMID:19303870 PMID:25512378 |
|
NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc10a2 |
solute carrier family 10 member 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [deoxynivalenol results in decreased expression of SLC10A2 mRNA] |
CTD |
PMID:37315771 |
|
NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475
|
|
G |
Slc20a1 |
solute carrier family 20 member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC20A1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 3:116,427,095...116,441,049
Ensembl chr 3:116,427,098...116,441,051
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cocaine results in increased expression of SLC6A2 protein] |
CTD |
PMID:25724654 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc7a1 |
solute carrier family 7 member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SLC7A11 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
EXP |
[SB 203580 co-treated with 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one] inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein]; SB 203580 inhibits the reaction [Paraquat results in increased phosphorylation of SMAD2 protein] |
CTD |
PMID:25873302 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB2 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:18253093 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; SB 203580 inhibits the reaction [benz(a)anthracene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [benzo(k)fluoranthene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [indeno(1,2,3-cd)pyrene results in increased expression of SNAI1 mRNA]; SB 203580 inhibits the reaction [thymoquinone results in decreased expression of SNAI1 protein] |
CTD |
PMID:21635667 PMID:27060453 PMID:33396024 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein] |
CTD |
PMID:33396024 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Snora23 |
small nucleolar RNA, H/ACA box 23 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of SNORA23 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 1:164,091,024...164,091,206
Ensembl chr 1:164,091,024...164,091,206
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO EXP |
SB 203580 inhibits the reaction [MAPK11 protein results in increased phosphorylation of SOD2 protein] SB 203580 inhibits the reaction [[Paraquat results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2 mRNA] |
CTD |
PMID:24376630 PMID:24465521 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [resveratrol results in increased expression of SOX9] |
CTD |
PMID:24841706 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Hydrogen Peroxide promotes the reaction [SP1 protein results in increased expression of CAV1 protein]] |
CTD |
PMID:17108117 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sp7 |
Sp7 transcription factor |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of SP7 mRNA]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of SP7 protein] |
CTD |
PMID:31472278 |
|
NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of SPP1 protein] |
CTD |
PMID:19356721 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
EXP ISO |
SB 203580 inhibits the reaction [fenvalerate results in decreased expression of SQSTM1 protein]; SB 203580 inhibits the reaction [osthol inhibits the reaction [Antineoplastic Agents, Immunological results in increased expression of SQSTM1 protein]] SB 203580 inhibits the reaction [sodium arsenite affects the expression of SQSTM1 protein] |
CTD |
PMID:31734597 PMID:34861471 PMID:37769856 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srf |
serum response factor |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Anisomycin results in increased phosphorylation of SRF protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of SRF protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of SRF protein] |
CTD |
PMID:12660819 PMID:21712382 |
|
NCBI chr 9:14,426,453...14,435,734
Ensembl chr 9:14,426,472...14,435,733
|
|
G |
Srrt |
serrate, RNA effector molecule |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [sodium arsenite results in increased expression of SRRT protein] |
CTD |
PMID:26404762 |
|
NCBI chr12:19,392,578...19,406,098
Ensembl chr12:19,392,625...19,406,095
|
|
G |
Ssb |
small RNA binding exonuclease protection factor La |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [SSB protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:25915936 |
|
NCBI chr 3:54,616,616...54,626,203
Ensembl chr 3:54,616,619...54,626,203
|
|
G |
Star |
steroidogenic acute regulatory protein |
multiple interactions increases expression |
ISO EXP |
SB 203580 inhibits the reaction [LEP protein inhibits the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]] SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of STAR mRNA]; SB 203580 inhibits the reaction [nickel sulfate results in decreased expression of STAR protein] SB 203580 results in increased expression of STAR mRNA; SB 203580 results in increased expression of STAR protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [SB 203580 promotes the reaction [sodium arsenite results in increased expression of STAR mRNA]]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [SB 203580 results in increased expression of STAR mRNA]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; [N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide co-treated with SB 203580] inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid inhibits the reaction [[CRTC2 protein binds to CREB1 protein modified form] which binds to STAR promoter]]; SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of STAR protein]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [8-Bromo Cyclic Adenosine Monophosphate results in increased expression of STAR protein]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of STAR mRNA]; SB 203580 promotes the reaction [sodium arsenite results in increased expression of STAR protein] |
CTD |
PMID:15713539 PMID:19849856 PMID:29567110 PMID:33359577 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stat1 |
signal transducer and activator of transcription 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [IFNG protein results in increased phosphorylation of STAT1 protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased phosphorylation of STAT1 protein] |
CTD |
PMID:16355272 PMID:20525893 |
|
NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions increases phosphorylation |
ISO |
SB 203580 inhibits the reaction [1,2,5,8-tetrahydroxy anthraquinone results in decreased phosphorylation of STAT3 protein]; SB 203580 inhibits the reaction [1,4-naphthoquinone analog results in decreased phosphorylation of STAT3 protein] SB 203580 results in increased phosphorylation of STAT3 protein |
CTD |
PMID:30871965 PMID:33030807 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stat5a |
signal transducer and activator of transcription 5A |
multiple interactions |
ISO |
SB 203580 affects the reaction [JTE 907 affects the phosphorylation of STAT5A protein] |
CTD |
PMID:30552973 |
|
NCBI chr10:85,785,537...85,809,869
Ensembl chr10:85,785,537...85,809,866
|
|
G |
Sts |
steroid sulfatase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [IGF2 protein results in increased expression of STS mRNA] |
CTD |
PMID:24055520 |
|
NCBI chr X:42,225,131...42,233,403
Ensembl chr X:42,225,372...42,233,402
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Gallic Acid results in increased expression of SULT1A1 protein] |
CTD |
PMID:16308312 |
|
NCBI chr 1:181,272,022...181,276,750
Ensembl chr 1:181,272,023...181,275,562
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cadmium Chloride affects the localization of SUMO1 protein] |
CTD |
PMID:12508112 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Tac1 |
tachykinin, precursor 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [GR 73632 promotes the reaction [Capsaicin results in increased secretion of TAC1 protein]] |
CTD |
PMID:18809416 |
|
NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178
|
|
G |
Tac4 |
tachykinin precursor 4 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TAC4 mRNA] |
CTD |
PMID:22384199 |
|
NCBI chr10:80,207,824...80,216,156
Ensembl chr10:80,207,610...80,216,156
|
|
G |
Taf4b |
TATA-box binding protein associated factor 4b |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of TAF4B mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr18:5,952,737...6,086,408
Ensembl chr18:5,952,769...6,068,307
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
ISO |
[pyrazolanthrone co-treated with SB 203580 co-treated with U 0126] inhibits the reaction [Isothiocyanates results in increased expression of TERT mRNA] |
CTD |
PMID:23382840 |
|
NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Tff1 |
trefoil factor 1 |
multiple interactions |
ISO |
SB 203580 affects the reaction [deoxynivalenol affects the expression of TFF1 mRNA] |
CTD |
PMID:30854615 |
|
NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597
|
|
G |
Tff2 |
trefoil factor 2 |
multiple interactions |
ISO |
SB 203580 affects the reaction [deoxynivalenol affects the expression of TFF2 mRNA] |
CTD |
PMID:30854615 |
|
NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,215,761...9,219,619
|
|
G |
Tff3 |
trefoil factor 3 |
multiple interactions |
ISO |
SB 203580 affects the reaction [deoxynivalenol affects the expression of TFF3 mRNA] |
CTD |
PMID:30854615 |
|
NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO EXP |
SB 203580 analog inhibits the reaction [TGFB1 protein results in increased expression of CCN2 protein]; SB 203580 inhibits the reaction [Asbestos, Serpentine results in increased secretion of TGFB1 protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of TGFB1 protein]; SB 203580 inhibits the reaction [TGFB1 protein affects the localization of JUNB protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CCND1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in decreased expression of KLF5 mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ACTA2 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of CNN1 protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of ITGB6 mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of JUNB mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR143]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MIR145]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of MYOCD mRNA]; SB 203580 inhibits the reaction [TGFB1 protein results in increased expression of SRF protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased phosphorylation of ATF2 protein] SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of TGFB1 protein]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of and results in decreased secretion of IGF1 protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of IL1B protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of TNF protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of ITGAM protein]]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of NOS2 protein]] SB 203580 inhibits the reaction [[Calcitriol co-treated with TGFB1 protein] results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Vehicle Emissions results in increased expression of TGFB1 mRNA] |
CTD |
PMID:11591817 PMID:12649123 PMID:16598785 PMID:19778233 PMID:21303922 PMID:21712382 PMID:25358858 PMID:26054450 PMID:26254549 PMID:28694203 PMID:35006638 More...
|
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [TGFB2 protein results in increased expression of COL1A1 mRNA]; SB 203580 inhibits the reaction [TGFB2 protein results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:18253093 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [fenvalerate results in decreased expression of TH protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of TH protein] |
CTD |
PMID:9288946 PMID:31734597 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Thbs1 |
thrombospondin 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Fluorouracil results in increased expression of THBS1 mRNA] |
CTD |
PMID:18757417 |
|
NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Dronabinol results in increased expression of TIMP1 protein]; SB 203580 inhibits the reaction [methanandamide results in increased expression of TIMP1 protein]; SB 203580 inhibits the reaction [thymoquinone results in increased expression of TIMP1 protein] |
CTD |
PMID:18159069 PMID:27060453 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [thymoquinone results in increased expression of TIMP2 protein] |
CTD |
PMID:27060453 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tjp1 |
tight junction protein 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [clopidogrel results in decreased expression of TJP1 protein] SB 203580 inhibits the reaction [perfluorooctane sulfonic acid results in decreased expression of TJP1 protein] |
CTD |
PMID:23220562 PMID:23761298 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tlr2 |
toll-like receptor 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TLR2 mRNA] |
CTD |
PMID:12888452 |
|
NCBI chr 2:169,200,620...169,206,819
Ensembl chr 2:169,197,419...169,206,630
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression increases expression decreases response to substance |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [SB 203580 inhibits the reaction [Lead results in increased expression of and results in increased stability of TNF mRNA]]; [nickel monoxide co-treated with SB 203580] results in decreased expression of TNF protein; [pirinixic acid co-treated with SB 203580] inhibits the reaction [TNF protein results in decreased expression of APOA1 mRNA]; SB 203580 inhibits the reaction [2,2-dichloroacetyl chloride results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [[IFNG protein co-treated with IL1B protein co-treated with TNF protein] results in increased expression of NOS2 mRNA]; SB 203580 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcimycin] results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Asbestos, Crocidolite results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Buthionine Sulfoximine promotes the reaction [TNF protein results in increased expression of CCL5 protein]]; SB 203580 inhibits the reaction [DDT results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [deoxynivalenol inhibits the reaction [[IFNG protein co-treated with TNF protein co-treated with IL1B protein] results in increased expression of NOS2 protein]]; SB 203580 inhibits the reaction [IL17A protein promotes the reaction [TNF protein results in increased expression of IL6 mRNA]]; SB 203580 inhibits the reaction [Lead results in increased expression of and results in increased stability of TNF mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Methotrexate results in decreased expression of TNF protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Mustard Gas results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [nickel monoxide results in increased expression of TNF protein]; SB 203580 inhibits the reaction [nickel sulfate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [nonylphenol results in increased expression of and results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [nonylphenol results in increased expression of TNF]; SB 203580 inhibits the reaction [Poly I-C results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Shiga Toxin results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of and results in increased activity of MMP9 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of F3 mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of FOS mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of and results in increased activity of ALOX5 protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of EIF4E protein]; SB 203580 inhibits the reaction [TNF results in increased expression of CCL2 protein]; SB 203580 inhibits the reaction [TNF results in increased expression of ICAM1 protein]; SB 203580 promotes the reaction [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Lead results in increased expression of and results in increased stability of TNF mRNA]]; SB 203580 promotes the reaction [[sodium arsenite co-treated with TNF protein] results in increased cleavage of PARP1 protein]; SB 203580 promotes the reaction [bufalin results in increased expression of TNF mRNA]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK1 protein]; SB 203580 promotes the reaction [TNF protein results in increased phosphorylation of MAPK3 protein]; SB 203580 promotes the reaction [Zymosan results in increased secretion of TNF protein] [SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of HSPB1 protein; [SB 203580 inhibits the reaction [Lipopolysaccharides co-treated with TNF protein]] which results in increased phosphorylation of MAPK14 protein; SB 203580 inhibits the reaction [2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; SB 203580 inhibits the reaction [7-Ala-angiotensin (1-7) inhibits the reaction [ACE2 protein inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]]]; SB 203580 inhibits the reaction [lead acetate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Manganese promotes the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]]; SB 203580 inhibits the reaction [Particulate Matter results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Resveratrol results in decreased expression of TNF protein] SB 203580 results in decreased expression of TNF protein [SB 203580 co-treated with U 0126] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [[Polysaccharides co-treated with IFNG protein] results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNF protein]; SB 203580 inhibits the reaction [cobaltous chloride results in increased expression of TNF protein]; SB 203580 inhibits the reaction [CPG-oligonucleotide results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]]; SB 203580 inhibits the reaction [deoxynivalenol promotes the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]; SB 203580 inhibits the reaction [deoxynivalenol results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [deoxynivalenol results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Dextran Sulfate results in increased expression of TNF protein]; SB 203580 inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]; SB 203580 inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; SB 203580 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; SB 203580 inhibits the reaction [Mercuric Chloride results in increased expression of TNF mRNA]; SB 203580 inhibits the reaction [Paraquat promotes the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]]; SB 203580 inhibits the reaction [Paraquat results in increased expression of TNF protein]; SB 203580 inhibits the reaction [TGFB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of and results in increased secretion of TNF protein]]; SB 203580 inhibits the reaction [TNF protein results in increased expression of CCL11 protein]; SB 203580 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; SB 203580 inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; SB 203580 promotes the reaction [PARK7 gene mutant form inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]] SB 203580 results in increased expression of TNF mRNA SB 203580 results in decreased susceptibility to TNF protein |
CTD |
PMID:1970628 PMID:9545260 PMID:9799232 PMID:10712238 PMID:10779545 PMID:11167962 PMID:11543732 PMID:11675405 PMID:12016129 PMID:12608646 PMID:14644621 PMID:15050407 PMID:15251176 PMID:15322261 PMID:15588916 PMID:15603917 PMID:15701814 PMID:15795323 PMID:16091123 PMID:16431125 PMID:16488514 PMID:16919916 PMID:17464197 PMID:17698565 PMID:18314537 PMID:18515973 PMID:19020780 PMID:19100307 PMID:19883121 PMID:20056579 PMID:20118172 PMID:20143454 PMID:20712904 PMID:20932985 PMID:21192278 PMID:21377791 PMID:22036725 PMID:22472292 PMID:22705379 PMID:22728154 PMID:23268108 PMID:23535185 PMID:23690655 PMID:23707484 PMID:23831309 PMID:24039973 PMID:24525298 PMID:25352548 PMID:25766886 PMID:26254549 PMID:26691871 PMID:27302421 PMID:27920472 PMID:28483571 PMID:28629242 PMID:29479036 PMID:29906494 PMID:31199065 PMID:33930529 PMID:35006638 PMID:35499276 PMID:36049518 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
decreases expression |
ISO |
SB 203580 results in decreased expression of TNFAIP6 mRNA |
CTD |
PMID:20660070 |
|
NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
multiple interactions decreases expression |
ISO |
SB 203580 inhibits the reaction [IL1B protein results in decreased expression of TNFRSF11B protein]; SB 203580 promotes the reaction [[Estradiol co-treated with Progesterone] results in decreased expression of TNFRSF11B mRNA] SB 203580 inhibits the reaction [Alprostadil results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Dinoprost results in increased expression of and results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Dinoprostone results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [FGF2 protein results in increased secretion of TNFRSF11B protein]; SB 203580 inhibits the reaction [Prostaglandin D2 results in increased secretion of TNFRSF11B protein] SB 203580 results in decreased expression of TNFRSF11B mRNA |
CTD |
PMID:20660070 PMID:22727857 PMID:24333336 PMID:24813642 PMID:25234201 PMID:25290095 PMID:25677506 More...
|
|
NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNFRSF1A protein] |
CTD |
PMID:15701814 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cisplatin results in increased expression of TNFRSF1B protein] |
CTD |
PMID:15701814 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance multiple interactions |
ISO |
SB 203580 results in increased susceptibility to TNFSF10 protein SB 203580 inhibits the reaction [CSC-3436 promotes the reaction [TNFSF10 protein results in increased cleavage of PARP1 protein]]; SB 203580 inhibits the reaction [TNFSF10 protein promotes the reaction [CSC-3436 results in increased cleavage of PARP1 protein]] |
CTD |
PMID:19497411 PMID:34599545 |
|
NCBI chr 2:110,199,835...110,227,239
Ensembl chr 2:110,207,916...110,225,135
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of ATP6V0D2 mRNA; [SB 203580 co-treated with sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in decreased expression of CTSK mRNA; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of ATP6V0D2 mRNA]]; SB 203580 affects the reaction [[NFE2L2 protein affects the susceptibility to sodium arsenite] affects the reaction [[CSF1R protein co-treated with TNFSF11 protein] affects the expression of CTSK mRNA]]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of ATP6V0D2 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with CSF1R protein co-treated with TNFSF11 protein] results in increased expression of CTSK mRNA] |
CTD |
PMID:30742845 |
|
NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP ISO |
SB 203580 inhibits the reaction [dibenzo(a,l)pyrene results in increased phosphorylation of TP53 protein] SB 203580 inhibits the reaction [deoxynivalenol results in increased phosphorylation of and results in increased activity of TRP53 protein]; SB 203580 inhibits the reaction [Ethanol results in increased expression of and results in increased phosphorylation of TP53 protein] SB 203580 inhibits the reaction [[Cisplatin co-treated with fisetin] results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [[sodium arsenite co-treated with Vitamin K 3] results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [Curcumin results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [icaritin results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [Pyrogallol results in increased expression of TP53 protein]; SB 203580 inhibits the reaction [S-allylcysteine results in increased phosphorylation of TP53 protein]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of TP53 protein]; SB 203580 inhibits the reaction [Sulindac affects the localization of TP53 protein] |
CTD |
PMID:15734884 PMID:15976193 PMID:16005925 PMID:17136320 PMID:19020741 PMID:19082730 PMID:20191265 PMID:21216935 PMID:27270636 PMID:31067004 PMID:38431053 More...
|
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpp2 |
tripeptidyl peptidase 2 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Etoposide affects the localization of TPP2 protein] |
CTD |
PMID:20643100 |
|
NCBI chr 9:46,046,712...46,128,157
Ensembl chr 9:46,046,632...46,128,157
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [GR 73632 results in increased phosphorylation of TRPV1 protein] |
CTD |
PMID:18809416 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Tsc22d1 |
TSC22 domain family, member 1 |
increases expression |
EXP |
SB 203580 results in increased expression of TSC22D1 mRNA |
CTD |
PMID:26464165 |
|
NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 protein]; SB 203580 inhibits the reaction [thymoquinone results in decreased expression of TWIST1 protein] |
CTD |
PMID:27060453 PMID:33396024 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of TXNRD1 mRNA] |
CTD |
PMID:28329830 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Tymp |
thymidine phosphorylase |
decreases expression multiple interactions |
ISO |
SB 203580 results in decreased expression of TYMP mRNA SB 203580 inhibits the reaction [salinomycin results in increased expression of TYMP mRNA]; SB 203580 promotes the reaction [[tanespimycin co-treated with salinomycin] results in decreased expression of TYMP mRNA] |
CTD |
PMID:30796972 |
|
NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874 Ensembl chr 7:120,438,770...120,443,874
|
|
G |
Tyr |
tyrosinase |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cannabidiol results in increased activity of TYR protein]; SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYR mRNA] SB 203580 inhibits the reaction [[resorcinol co-treated with Cycloheximide] results in increased expression of TYR protein]; SB 203580 inhibits the reaction [resorcinol results in decreased activity of TYR protein] |
CTD |
PMID:28601556 PMID:29621941 |
|
NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
|
|
G |
Tyrp1 |
tyrosinase-related protein 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Cannabidiol results in increased expression of TYRP1 mRNA] |
CTD |
PMID:28601556 |
|
NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
|
|
G |
Ucp3 |
uncoupling protein 3 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of UCP3 protein] |
CTD |
PMID:18579531 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [chrysin results in increased expression of UGT1A1 mRNA] |
CTD |
PMID:17256720 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vasp |
vasodilator-stimulated phosphoprotein |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VASP protein] |
CTD |
PMID:24677693 |
|
NCBI chr 1:78,910,009...78,925,791
Ensembl chr 1:78,910,011...78,925,061
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [Chenodeoxycholic Acid results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [EDN1 protein results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [melamine results in increased expression of VCAM1 mRNA] SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of VCAM1 mRNA]; SB 203580 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein] |
CTD |
PMID:16582018 PMID:18457675 PMID:22915474 PMID:28329830 PMID:28483571 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases secretion decreases expression |
ISO EXP |
SB 203580 inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [4-tert-octylphenol results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [butylbenzyl phthalate results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Dieldrin results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Estradiol results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Genistein results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]]; SB 203580 inhibits the reaction [Melitten results in decreased expression of VEGFA protein]; SB 203580 inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [sodium arsenite results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [Troglitazone results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [Troglitazone results in increased expression of VEGFA protein]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 mRNA]; SB 203580 inhibits the reaction [VEGFA protein results in increased expression of PTGS2 protein] SB 203580 results in decreased secretion of VEGFA protein SB 203580 inhibits the reaction [[Calcitriol co-treated with TGFB1 protein] results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [Calcitriol results in increased secretion of VEGFA protein]; SB 203580 inhibits the reaction [TGFB1 protein results in increased secretion of VEGFA protein] SB 203580 results in decreased expression of VEGFA mRNA; SB 203580 results in decreased expression of VEGFA protein SB 203580 inhibits the reaction [[1-methylanthracene co-treated with fluoranthene] results in increased expression of VEGFA mRNA]; SB 203580 inhibits the reaction [arsenic trioxide results in increased expression of VEGFA mRNA] |
CTD |
PMID:12482858 PMID:13679210 PMID:16598785 PMID:18252963 PMID:18596194 PMID:18599600 PMID:19779139 PMID:22488045 PMID:23110475 PMID:23968725 PMID:28329830 PMID:30801954 PMID:32890875 More...
|
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
decreases secretion |
ISO |
SB 203580 results in decreased secretion of VEGFC protein |
CTD |
PMID:19779139 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM mRNA]; SB 203580 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein]; SB 203580 inhibits the reaction [Amiodarone results in increased expression of VIM mRNA]; SB 203580 inhibits the reaction [Amiodarone results in increased expression of VIM protein]; SB 203580 inhibits the reaction [cyanoginosin LR results in increased phosphorylation of VIM protein]; SB 203580 inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VIM protein] |
CTD |
PMID:22960429 PMID:26971374 PMID:31071512 PMID:33396024 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Xdh |
xanthine dehydrogenase |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Oxygen deficiency results in increased phosphorylation of and results in increased activity of XDH protein] |
CTD |
PMID:11278616 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
decreases expression |
ISO |
SB 203580 results in decreased expression of XIAP protein |
CTD |
PMID:30801954 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
G |
Zc3h12a |
zinc finger CCCH type containing 12A |
multiple interactions |
EXP |
SB 203580 inhibits the reaction [Silicon Dioxide results in increased expression of ZC3H12A protein] |
CTD |
PMID:26865670 |
|
NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351
|
|
G |
Zfp36 |
zinc finger protein 36 |
multiple interactions |
ISO |
SB 203580 inhibits the reaction [isoeugenol results in increased expression of ZFP36 protein] |
CTD |
PMID:21969073 |
|
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
|
|